ID   FGFR3_HUMAN             Reviewed;         806 AA.
AC   P22607; D3DVP9; D3DVQ0; Q14308; Q16294; Q16608; Q59FL9;
DT   01-AUG-1991, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1991, sequence version 1.
DT   12-OCT-2022, entry version 255.
DE   RecName: Full=Fibroblast growth factor receptor 3;
DE            Short=FGFR-3;
DE            EC=2.7.10.1;
DE   AltName: CD_antigen=CD333;
DE   Flags: Precursor;
GN   Name=FGFR3; Synonyms=JTK4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=1847508; DOI=10.1073/pnas.88.4.1095;
RA   Keegan K., Johnson D.E., Williams L.T., Hayman M.J.;
RT   "Isolation of an additional member of the fibroblast growth factor receptor
RT   family, FGFR-3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:1095-1099(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION, SUBUNIT, FGF1- AND
RP   FGF2-BINDING, SUBCELLULAR LOCATION, GLYCOSYLATION, AND DIMERIZATION.
RC   TISSUE=Squamous cell carcinoma;
RX   PubMed=11703096; DOI=10.1006/mcbr.2001.0306;
RA   Terada M., Shimizu A., Sato N., Miyakaze S.I., Katayama H.,
RA   Kurokawa-Seo M.;
RT   "Fibroblast growth factor receptor 3 lacking the Ig IIIb and transmembrane
RT   domains secreted from human squamous cell carcinoma DJM-1 binds to FGFs.";
RL   Mol. Cell Biol. Res. Commun. 4:365-373(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ARG-65; LEU-384; THR-441;
RP   THR-717 AND PHE-726.
RG   NIEHS SNPs program;
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H., Minx P.,
RA   Wagner-McPherson C., Layman D., Wylie K., Sekhon M., Becker M.C.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Kremitzki C., Oddy L.,
RA   Du H., Sun H., Bradshaw-Cordum H., Ali J., Carter J., Cordes M., Harris A.,
RA   Isak A., van Brunt A., Nguyen C., Du F., Courtney L., Kalicki J.,
RA   Ozersky P., Abbott S., Armstrong J., Belter E.A., Caruso L., Cedroni M.,
RA   Cotton M., Davidson T., Desai A., Elliott G., Erb T., Fronick C., Gaige T.,
RA   Haakenson W., Haglund K., Holmes A., Harkins R., Kim K., Kruchowski S.S.,
RA   Strong C.M., Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N., Swearengen-Shahid S.,
RA   Snider J., Strong J.T., Thompson J., Yoakum M., Leonard S., Pearman C.,
RA   Trani L., Radionenko M., Waligorski J.E., Wang C., Rock S.M.,
RA   Tin-Wollam A.-M., Maupin R., Latreille P., Wendl M.C., Yang S.-P., Pohl C.,
RA   Wallis J.W., Spieth J., Bieri T.A., Berkowicz N., Nelson J.O., Osborne J.,
RA   Ding L., Meyer R., Sabo A., Shotland Y., Sinha P., Wohldmann P.E.,
RA   Cook L.L., Hickenbotham M.T., Eldred J., Williams D., Jones T.A., She X.,
RA   Ciccarelli F.D., Izaurralde E., Taylor J., Schmutz J., Myers R.M.,
RA   Cox D.R., Huang X., McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D., Waterston R.H.,
RA   Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2 and
RT   4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 76-806 (ISOFORM 1), AND TISSUE SPECIFICITY.
RC   TISSUE=Fetal brain;
RX   PubMed=1664411; DOI=10.1016/0888-7543(91)90041-c;
RA   Thompson L.M., Plummer S., Schalling M., Altherr M.R., Gusella J.F.,
RA   Housman D.E., Wasmuth J.J.;
RT   "A gene encoding a fibroblast growth factor receptor isolated from the
RT   Huntington disease gene region of human chromosome 4.";
RL   Genomics 11:1133-1142(1991).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 614-681.
RX   PubMed=2247464; DOI=10.1073/pnas.87.22.8913;
RA   Partanen J., Maekelae T.P., Alitalo R., Lehvaeslaiho H., Alitalo K.;
RT   "Putative tyrosine kinases expressed in K-562 human leukemia cells.";
RL   Proc. Natl. Acad. Sci. U.S.A. 87:8913-8917(1990).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Colon tumor;
RX   PubMed=7923141;
RA   Murgue B., Tsunekawa S., Rosenberg I., deBeaumont M., Podolsky D.K.;
RT   "Identification of a novel variant form of fibroblast growth factor
RT   receptor 3 (FGFR3 IIIb) in human colonic epithelium.";
RL   Cancer Res. 54:5206-5211(1994).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 311-358 (ISOFORM 2).
RC   TISSUE=Keratinocyte;
RX   PubMed=7495869; DOI=10.1016/0167-4781(95)00156-b;
RA   Scotet E., Houssaint E.;
RT   "The choice between alternative IIIb and IIIc exons of the FGFR-3 gene is
RT   not strictly tissue-specific.";
RL   Biochim. Biophys. Acta 1264:238-242(1995).
RN   [11]
RP   INTERACTION WITH FGF1; FGF2; FGF4; FGF8 AND FGF9, AND FUNCTION IN CELL
RP   PROLIFERATION.
RX   PubMed=8663044; DOI=10.1074/jbc.271.25.15292;
RA   Ornitz D.M., Xu J., Colvin J.S., McEwen D.G., MacArthur C.A., Coulier F.,
RA   Gao G., Goldfarb M.;
RT   "Receptor specificity of the fibroblast growth factor family.";
RL   J. Biol. Chem. 271:15292-15297(1996).
RN   [12]
RP   INVOLVEMENT IN SADDAN, VARIANT SADDAN MET-650, AND CHARACTERIZATION OF
RP   VARIANT SADDAN MET-650.
RX   PubMed=10053006; DOI=10.1086/302275;
RA   Tavormina P.L., Bellus G.A., Webster M.K., Bamshad M.J., Fraley A.E.,
RA   McIntosh I., Szabo J., Jiang W., Jabs E.W., Wilcox W.R., Wasmuth J.J.,
RA   Donoghue D.J., Thompson L.M., Francomano C.A.;
RT   "A novel skeletal dysplasia with developmental delay and acanthosis
RT   nigricans is caused by a Lys650Met mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   Am. J. Hum. Genet. 64:722-731(1999).
RN   [13]
RP   FUNCTION AS FGF9 RECEPTOR IN CHONDROCYTES AND IN ACTIVATION OF SIGNALING
RP   PATHWAYS, SUBUNIT, SUBCELLULAR LOCATION, DEGRADATION, AUTOPHOSPHORYLATION,
RP   AND CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=10611230; DOI=10.1128/mcb.20.2.516-522.2000;
RA   Monsonego-Ornan E., Adar R., Feferman T., Segev O., Yayon A.;
RT   "The transmembrane mutation G380R in fibroblast growth factor receptor 3
RT   uncouples ligand-mediated receptor activation from down-regulation.";
RL   Mol. Cell. Biol. 20:516-522(2000).
RN   [14]
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION; PHOSPHORYLATION OF PIK3R1;
RP   PTPN11/SHP2; STAT1; STAT3 AND MAP KINASES, PHOSPHORYLATION AT TYR-724,
RP   MUTAGENESIS OF TYR-577; TYR-724; TYR-760 AND TYR-770, AND CHARACTERIZATION
RP   OF VARIANT GLU-650.
RX   PubMed=11294897; DOI=10.1091/mbc.12.4.931;
RA   Hart K.C., Robertson S.C., Donoghue D.J.;
RT   "Identification of tyrosine residues in constitutively activated fibroblast
RT   growth factor receptor 3 involved in mitogenesis, Stat activation, and
RT   phosphatidylinositol 3-kinase activation.";
RL   Mol. Biol. Cell 12:931-942(2001).
RN   [15]
RP   UBIQUITINATION, PHOSPHORYLATION, CATALYTIC ACTIVITY, MUTAGENESIS OF
RP   LYS-508, CHARACTERIZATION OF VARIANT ACH ARG-380, AND CHARACTERIZATION OF
RP   VARIANT TD2 GLU-650.
RX   PubMed=12297284; DOI=10.1016/s0014-5793(02)03255-6;
RA   Monsonego-Ornan E., Adar R., Rom E., Yayon A.;
RT   "FGF receptors ubiquitylation: dependence on tyrosine kinase activity and
RT   role in downregulation.";
RL   FEBS Lett. 528:83-89(2002).
RN   [16]
RP   FUNCTION AS PROTO-ONCOGENE IN ACTIVATION OF SIGNALING AND CELL
RP   PROLIFERATION, FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF
RP   VARIANT GLU-650, AND AUTOPHOSPHORYLATION.
RX   PubMed=14534538; DOI=10.1038/sj.onc.1206798;
RA   Agazie Y.M., Movilla N., Ischenko I., Hayman M.J.;
RT   "The phosphotyrosine phosphatase SHP2 is a critical mediator of
RT   transformation induced by the oncogenic fibroblast growth factor receptor
RT   3.";
RL   Oncogene 22:6909-6918(2003).
RN   [17]
RP   INTERACTION WITH FGF1; FGF8; FGF9; FGF17; FGF18; FGF19 AND FGF20, AND
RP   FUNCTION IN STIMULATION OF CELL PROLIFERATION.
RX   PubMed=16597617; DOI=10.1074/jbc.m601252200;
RA   Zhang X., Ibrahimi O.A., Olsen S.K., Umemori H., Mohammadi M., Ornitz D.M.;
RT   "Receptor specificity of the fibroblast growth factor family. The complete
RT   mammalian FGF family.";
RL   J. Biol. Chem. 281:15694-15700(2006).
RN   [18]
RP   INTERACTION WITH SOCS1 AND SOCS3, FUNCTION IN ACTIVATION OF STAT1 AND MAP
RP   KINASES, GLYCOSYLATION, PHOSPHORYLATION, MUTAGENESIS OF LYS-508, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=16410555; DOI=10.1242/jcs.02740;
RA   Ben-Zvi T., Yayon A., Gertler A., Monsonego-Ornan E.;
RT   "Suppressors of cytokine signaling (SOCS) 1 and SOCS3 interact with and
RT   modulate fibroblast growth factor receptor signaling.";
RL   J. Cell Sci. 119:380-387(2006).
RN   [19]
RP   FUNCTION IN REGULATION OF CHONDROCYTE PROLIFERATION AND IN ACTIVATION OF
RP   PLCG1 AND STAT1, INTERACTION WITH FHF1 AND HEPARIN, SUBCELLULAR LOCATION,
RP   PHOSPHORYLATION, AND CHARACTERIZATION OF VARIANTS ARG-380; GLU-650 AND
RP   MET-650.
RX   PubMed=17561467; DOI=10.1016/j.bone.2006.11.030;
RA   Harada D., Yamanaka Y., Ueda K., Nishimura R., Morishima T., Seino Y.,
RA   Tanaka H.;
RT   "Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic
RT   dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via
RT   PLCgamma-activated STAT1.";
RL   Bone 41:273-281(2007).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF CBL, UBIQUITINATION, GLYCOSYLATION,
RP   SUBCELLULAR LOCATION, ACTIVITY REGULATION, AND CHARACTERIZATION OF VARIANTS
RP   CYS-248; CYS-373 AND MET-650.
RX   PubMed=17509076; DOI=10.1111/j.1742-4658.2007.05835.x;
RA   Bonaventure J., Horne W.C., Baron R.;
RT   "The localization of FGFR3 mutations causing thanatophoric dysplasia type I
RT   differentially affects phosphorylation, processing and ubiquitylation of
RT   the receptor.";
RL   FEBS J. 274:3078-3093(2007).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF FRS2, CHARACTERIZATION OF VARIANT GLU-650,
RP   ACTIVITY REGULATION, AND CATALYTIC ACTIVITY.
RX   PubMed=17145761; DOI=10.1074/jbc.m606144200;
RA   Krejci P., Masri B., Salazar L., Farrington-Rock C., Prats H.,
RA   Thompson L.M., Wilcox W.R.;
RT   "Bisindolylmaleimide I suppresses fibroblast growth factor-mediated
RT   activation of Erk MAP kinase in chondrocytes by preventing Shp2 association
RT   with the Frs2 and Gab1 adaptor proteins.";
RL   J. Biol. Chem. 282:2929-2936(2007).
RN   [22]
RP   INTERACTION WITH FGF19; FGF21 AND KLB.
RX   PubMed=17623664; DOI=10.1074/jbc.m704165200;
RA   Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V.,
RA   Mohammadi M., Rosenblatt K.P., Kliewer S.A., Kuro-o M.;
RT   "Tissue-specific expression of betaKlotho and fibroblast growth factor
RT   (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21.";
RL   J. Biol. Chem. 282:26687-26695(2007).
RN   [23]
RP   FUNCTION IN STAT1 PHOSPHORYLATION, GLYCOSYLATION, AND PHOSPHORYLATION.
RX   PubMed=17311277; DOI=10.1002/jcp.21014;
RA   Citores L., Bai L., Sorensen V., Olsnes S.;
RT   "Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the
RT   Golgi apparatus without translocation to the nucleus.";
RL   J. Cell. Physiol. 212:148-156(2007).
RN   [24]
RP   FUNCTION IN ACTIVATION OF STAT1; STAT5; MAPK1/ERK2; MAPK3/ERK1 AND THE MAP
RP   KINASE SIGNALING PATHWAY.
RX   PubMed=19088846; DOI=10.1371/journal.pone.0003961;
RA   Krejci P., Salazar L., Kashiwada T.A., Chlebova K., Salasova A.,
RA   Thompson L.M., Bryja V., Kozubik A., Wilcox W.R.;
RT   "Analysis of STAT1 activation by six FGFR3 mutants associated with skeletal
RT   dysplasia undermines dominant role of STAT1 in FGFR3 signaling in
RT   cartilage.";
RL   PLoS ONE 3:E3961-E3961(2008).
RN   [25]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [26]
RP   FUNCTION, INTERACTION WITH PIK3R1 AND PLCG1, AND PHOSPHORYLATION AT
RP   TYR-760.
RX   PubMed=19286672; DOI=10.1093/hmg/ddp116;
RA   Salazar L., Kashiwada T., Krejci P., Muchowski P., Donoghue D.,
RA   Wilcox W.R., Thompson L.M.;
RT   "A novel interaction between fibroblast growth factor receptor 3 and the
RT   p85 subunit of phosphoinositide 3-kinase: activation-dependent regulation
RT   of ERK by p85 in multiple myeloma cells.";
RL   Hum. Mol. Genet. 18:1951-1961(2009).
RN   [27]
RP   REVIEW ON FUNCTION; ALTERNATIVE SPLICING; SIGNALING AND ROLE IN DISEASE.
RX   PubMed=15863030; DOI=10.1016/j.cytogfr.2005.01.001;
RA   Eswarakumar V.P., Lax I., Schlessinger J.;
RT   "Cellular signaling by fibroblast growth factor receptors.";
RL   Cytokine Growth Factor Rev. 16:139-149(2005).
RN   [28]
RP   REVIEW ON FUNCTION; LIGANDS; SIGNALING; ALTERNATIVE SPLICING; DOMAIN; ROLE
RP   IN DISEASE; UBIQUITINATION AND DEGRADATION.
RX   PubMed=15748888; DOI=10.1016/j.yexcr.2004.11.012;
RA   L'Hote C.G., Knowles M.A.;
RT   "Cell responses to FGFR3 signalling: growth, differentiation and
RT   apoptosis.";
RL   Exp. Cell Res. 304:417-431(2005).
RN   [29]
RP   REVIEW ON ROLE IN SKELETON DEVELOPMENT AND DISEASE.
RX   PubMed=19066716; DOI=10.1007/s00774-008-0009-7;
RA   Harada D., Yamanaka Y., Ueda K., Tanaka H., Seino Y.;
RT   "FGFR3-related dwarfism and cell signaling.";
RL   J. Bone Miner. Metab. 27:9-15(2009).
RN   [30]
RP   REVIEW ON FUNCTION IN FGF SIGNALING.
RX   PubMed=20094046; DOI=10.1038/nrc2780;
RA   Turner N., Grose R.;
RT   "Fibroblast growth factor signalling: from development to cancer.";
RL   Nat. Rev. Cancer 10:116-129(2010).
RN   [31]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (3.2 ANGSTROMS) OF 32-365 IN COMPLEX WITH FGF1,
RP   ACTIVITY REGULATION, AND DOMAIN.
RX   PubMed=14732692; DOI=10.1073/pnas.0307287101;
RA   Olsen S.K., Ibrahimi O.A., Raucci A., Zhang F., Eliseenkova A.V., Yayon A.,
RA   Basilico C., Linhardt R.J., Schlessinger J., Mohammadi M.;
RT   "Insights into the molecular basis for fibroblast growth factor receptor
RT   autoinhibition and ligand-binding promiscuity.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:935-940(2004).
RN   [33]
RP   VARIANT ACH ARG-380.
RX   PubMed=8078586; DOI=10.1038/371252a0;
RA   Rousseau F., Bonaventure J., Legeai-Mallet L., Pelet A., Rozet J.-M.,
RA   Maroteaux P., le Merrer M., Munnich A.;
RT   "Mutations in the gene encoding fibroblast growth factor receptor-3 in
RT   achondroplasia.";
RL   Nature 371:252-254(1994).
RN   [34]
RP   VARIANT ACH ARG-380.
RX   PubMed=7847369;
RA   Bellus G.A., Hefferon T.W., de Luna R.I., Hecht J.T., Horton W.A.,
RA   Machado M., Kaitila I., McIntosh I., Francomano C.A.;
RT   "Achondroplasia is defined by recurrent G380R mutations of FGFR3.";
RL   Am. J. Hum. Genet. 56:368-373(1995).
RN   [35]
RP   VARIANT ACH CYS-375.
RX   PubMed=7758520; DOI=10.1007/bf01954274;
RA   Superti-Furga A., Eich G., Bucher H.U., Wisser J., Giedion A.,
RA   Gitzelmann R., Steinmann B.;
RT   "A glycine 375-to-cysteine substitution in the transmembrane domain of the
RT   fibroblast growth factor receptor-3 in a newborn with achondroplasia.";
RL   Eur. J. Pediatr. 154:215-219(1995).
RN   [36]
RP   VARIANT TD1 CYS-249.
RX   PubMed=8589699; DOI=10.1093/hmg/4.11.2175;
RA   Tavormina P.L., Rimoin D.L., Cohn D.H., Zhu Y.-Z., Shiang R., Wasmuth J.J.;
RT   "Another mutation that results in the substitution of an unpaired cysteine
RT   residue in the extracellular domain of FGFR3 in thanatophoric dysplasia
RT   type I.";
RL   Hum. Mol. Genet. 4:2175-2177(1995).
RN   [37]
RP   VARIANTS TD1 CYS-248 AND CYS-371, AND VARIANT TD2 GLU-650.
RX   PubMed=7773297; DOI=10.1038/ng0395-321;
RA   Tavormina P.L., Shiang R., Thompson L.M., Zhu Y.-Z., Wilkin D.J.,
RA   Lachman R.S., Wilcox W.R., Rimoin D.L., Cohn D.H., Wasmuth J.J.;
RT   "Thanatophoric dysplasia (types I and II) caused by distinct mutations in
RT   fibroblast growth factor receptor 3.";
RL   Nat. Genet. 9:321-328(1995).
RN   [38]
RP   VARIANT HYPOCHONDROPLASIA LYS-540.
RX   PubMed=7670477; DOI=10.1038/ng0795-357;
RA   Bellus G.A., McIntosh I., Smith E.A., Aylsworth A.S., Kaitila I.,
RA   Horton W.A., Greenhaw G.A., Hecht J.T., Francomano C.A.;
RT   "A recurrent mutation in the tyrosine kinase domain of fibroblast growth
RT   factor receptor 3 causes hypochondroplasia.";
RL   Nat. Genet. 10:357-359(1995).
RN   [39]
RP   VARIANT CAN GLU-391.
RX   PubMed=7493034; DOI=10.1038/ng1295-462;
RA   Meyers G.A., Orlow S.J., Munro I.R., Przylepa K.A., Jabs E.W.;
RT   "Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in
RT   Crouzon syndrome with acanthosis nigricans.";
RL   Nat. Genet. 11:462-464(1995).
RN   [40]
RP   CHARACTERIZATION OF VARIANT ACH ARG-380.
RX   PubMed=8599935; DOI=10.1002/j.1460-2075.1996.tb00384.x;
RA   Webster M.K., Donoghue D.J.;
RT   "Constitutive activation of fibroblast growth factor receptor 3 by the
RT   transmembrane domain point mutation found in achondroplasia.";
RL   EMBO J. 15:520-527(1996).
RN   [41]
RP   VARIANTS TD1 CYS-248; CYS-249; CYS-370 AND CYS-373.
RX   PubMed=8845844; DOI=10.1093/hmg/5.4.509;
RA   Rousseau F., el Ghouzzi V., Delezoide A.-L., Legeai-Mallet L.,
RA   le Merrer M., Munnich A., Bonaventure J.;
RT   "Missense FGFR3 mutations create cysteine residues in thanatophoric
RT   dwarfism type I (TD1).";
RL   Hum. Mol. Genet. 5:509-512(1996).
RN   [42]
RP   CHARACTERIZATION OF VARIANT TD2 GLU-650, CHARACTERIZATION OF VARIANT
RP   GLN-650, AND PHOSPHORYLATION AT TYR-647 AND TYR-648.
RX   PubMed=8754806; DOI=10.1128/mcb.16.8.4081;
RA   Webster M.K., D'Avis P.Y., Robertson S.C., Donoghue D.J.;
RT   "Profound ligand-independent kinase activation of fibroblast growth factor
RT   receptor 3 by the activation loop mutation responsible for a lethal
RT   skeletal dysplasia, thanatophoric dysplasia type II.";
RL   Mol. Cell. Biol. 16:4081-4087(1996).
RN   [43]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9042914;
RA   Muenke M., Gripp K.W., McDonald-Mcginn D.M., Gaudenz K., Whitaker L.A.,
RA   Bartlett S.P., Markowitz R.I., Robin N.H., Nwokoro N., Mulvihill J.J.,
RA   Losken H.W., Mulliken J.B., Guttmacher A.E., Wilroy R.S., Clarke L.A.,
RA   Hollway G., Ades L.C., Haan E.A., Mulley J.C., Cohen M.M. Jr., Bellus G.A.,
RA   Francomano C.A., Moloney D.M., Wall S.A., Wilkie A.O.M., Zackai E.H.;
RT   "A unique point mutation in the fibroblast growth factor receptor 3 gene
RT   (FGFR3) defines a new craniosynostosis syndrome.";
RL   Am. J. Hum. Genet. 60:555-564(1997).
RN   [44]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANTS CYS-373; GLU-650 AND MET-650.
RX   PubMed=9207791; DOI=10.1038/ng0797-260;
RA   Chesi M., Nardini E., Brents L.A., Schroeck E., Ried T., Kuehl W.M.,
RA   Bergsagel P.L.;
RT   "Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is
RT   associated with increased expression and activating mutations of fibroblast
RT   growth factor receptor 3.";
RL   Nat. Genet. 16:260-264(1997).
RN   [45]
RP   VARIANT TD1 CYS-370.
RX   PubMed=9790257; DOI=10.1507/endocrj.45.suppl_s171;
RA   Katsumata N., Kuno T., Miyazaki S., Mikami S., Nagashima-Miyokawa A.,
RA   Nimura A., Horikawa R., Tanaka T.;
RT   "G370C mutation in the FGFR3 gene in a Japanese patient with thanatophoric
RT   dysplasia.";
RL   Endocr. J. 45:S171-S174(1998).
RN   [46]
RP   VARIANT HYPOCHONDROPLASIA VAL-538.
RX   PubMed=10215410;
RA   Grigelioniene G., Hagenaes L., Ekloef O., Neumeyer L., Haereid P.E.,
RA   Anvret M.;
RT   "A novel missense mutation Ile538Val in the fibroblast growth factor
RT   receptor 3 in hypochondroplasia.";
RL   Hum. Mutat. 11:333-333(1998).
RN   [47]
RP   VARIANT HYPOCHONDROPLASIA THR-540.
RX   PubMed=9452043; DOI=10.1002/humu.1380110122;
RA   Deutz-Terlouw P.P., Losekoot M., Aalfs C.M., Hennekam R.C.M., Bakker E.;
RT   "Asn540Thr substitution in the fibroblast growth factor receptor 3 tyrosine
RT   kinase domain causing hypochondroplasia.";
RL   Hum. Mutat. Suppl. 1:S62-S65(1998).
RN   [48]
RP   VARIANT TD1 MET-650.
RX   PubMed=10671061;
RA   Kitoh H., Brodie S.G., Kupke K.G., Lachman R.S., Wilcox W.R.;
RT   "Lys650Met substitution in the tyrosine kinase domain of the fibroblast
RT   growth factor receptor gene causes thanatophoric dysplasia type I.";
RL   Hum. Mutat. 12:362-363(1998).
RN   [49]
RP   VARIANT ARG-250.
RX   PubMed=9525367; DOI=10.1016/s0140-6736(98)24012-8;
RA   Hollway G.E., Suthers G.K., Battese K.M., Turner A.M., David D.J.,
RA   Mulley J.C.;
RT   "Deafness due to Pro250Arg mutation of FGFR3.";
RL   Lancet 351:877-878(1998).
RN   [50]
RP   VARIANTS TD1 CYS-248; CYS-249 AND CYS-373.
RX   PubMed=10360402;
RX   DOI=10.1002/(sici)1096-8628(19990611)84:5<476::aid-ajmg12>3.0.co;2-x;
RA   Brodie S.G., Kitoh H., Lachman R.S., Nolasco L.M., Mekikian P.B.,
RA   Wilcox W.R.;
RT   "Platyspondylic lethal skeletal dysplasia, San Diego type, is caused by
RT   FGFR3 mutations.";
RL   Am. J. Med. Genet. 84:476-480(1999).
RN   [51]
RP   VARIANT MNKS ARG-250.
RX   PubMed=9950359;
RA   Lajeunie E., El Ghouzzi V., Le Merrer M., Munnich A., Bonaventure J.,
RA   Renier D.;
RT   "Sex related expressivity of the phenotype in coronal craniosynostosis
RT   caused by the recurrent P250R FGFR3 mutation.";
RL   J. Med. Genet. 36:9-13(1999).
RN   [52]
RP   VARIANTS BLC CYS-248; CYS-249; CYS-370 AND GLU-650, AND VARIANTS CERCA
RP   CYS-248; CYS-249; CYS-370 AND GLU-650.
RX   PubMed=10471491; DOI=10.1038/12615;
RA   Cappellen D., De Oliveira C., Ricol D., Gil Diez de Medina S., Bourdin J.,
RA   Sastre-Garau X., Chopin D., Thiery J.P., Radvanyi F.;
RT   "Frequent activating mutations of FGFR3 in human bladder and cervix
RT   carcinomas.";
RL   Nat. Genet. 23:18-20(1999).
RN   [53]
RP   VARIANT HYPOCHONDROPLASIA GLN-650.
RX   PubMed=11055896; DOI=10.1086/316892;
RA   Bellus G.A., Spector E.B., Speiser P.W., Weaver C.A., Garber A.T.,
RA   Bryke C.R., Israel J., Rosengren S.S., Webster M.K., Donoghue D.J.,
RA   Francomano C.A.;
RT   "Distinct missense mutations of the FGFR3 Lys650 codon modulate receptor
RT   kinase activation and the severity of the skeletal dysplasia phenotype.";
RL   Am. J. Hum. Genet. 67:1411-1421(2000).
RN   [54]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=10777366; DOI=10.1136/jmg.37.3.220;
RA   Mortier G., Nuytinck L., Craen M., Renard J.-P., Leroy J.G., De Paepe A.;
RT   "Clinical and radiographic features of a family with hypochondroplasia
RT   owing to a novel asn540ser mutation in the fibroblast growth factor
RT   receptor 3 gene.";
RL   J. Med. Genet. 37:220-224(2000).
RN   [55]
RP   VARIANT MNKS ARG-250.
RX   PubMed=11746040; DOI=10.1002/ajmg.10049;
RA   Lowry R.B., Jabs E.W., Graham G.E., Gerritsen J., Fleming J.;
RT   "Syndrome of coronal craniosynostosis, Klippel-Feil anomaly, and sprengel
RT   shoulder with and without Pro250Arg mutation in the FGFR3 gene.";
RL   Am. J. Med. Genet. 104:112-119(2001).
RN   [56]
RP   INVOLVEMENT IN MULTIPLE MYELOMA, AND VARIANT CYS-248.
RX   PubMed=11529856; DOI=10.1046/j.1365-2141.2001.02957.x;
RA   Intini D., Baldini L., Fabris S., Lombardi L., Ciceri G., Maiolo A.T.,
RA   Neri A.;
RT   "Analysis of FGFR3 gene mutations in multiple myeloma patients with
RT   t(4;14).";
RL   Br. J. Haematol. 114:362-364(2001).
RN   [57]
RP   VARIANT COLORECTAL CANCER LYS-322.
RX   PubMed=11325814;
RA   Jang J.-H., Shin K.-H., Park J.-G.;
RT   "Mutations in fibroblast growth factor receptor 2 and fibroblast growth
RT   factor receptor 3 genes associated with human gastric and colorectal
RT   cancers.";
RL   Cancer Res. 61:3541-3543(2001).
RN   [58]
RP   VARIANT BLC CANCER GLN-650.
RX   PubMed=11314002; DOI=10.1038/sj.onc.1204110;
RA   Sibley K., Cuthbert-Heavens D., Knowles M.A.;
RT   "Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional
RT   cell carcinoma.";
RL   Oncogene 20:686-691(2001).
RN   [59]
RP   VARIANT HYPOCHONDROPLASIA SER-540.
RX   PubMed=12707965; DOI=10.1002/ajmg.a.10238;
RA   Thauvin-Robinet C., Faivre L., Lewin P., De Monleon J.-V., Francois C.,
RA   Huet F., Couailler J.-F., Campos-Xavier A.B., Bonaventure J., Le Merrer M.;
RT   "Hypochondroplasia and stature within normal limits: another family with an
RT   Asn540-to-Ser mutation in the fibroblast growth factor receptor 3 gene.";
RL   Am. J. Med. Genet. A 119:81-84(2003).
RN   [60]
RP   VARIANTS KERSEB CYS-248; CYS-249; CYS-370; CYS-371; CYS-373; GLU-650 AND
RP   MET-650.
RX   PubMed=15772091; DOI=10.1093/hmg/ddi127;
RA   Logie A., Dunois-Larde C., Rosty C., Levrel O., Blanche M., Ribeiro A.,
RA   Gasc J.-M., Jorcano J., Werner S., Sastre-Garau X., Thiery J.P.,
RA   Radvanyi F.;
RT   "Activating mutations of the tyrosine kinase receptor FGFR3 are associated
RT   with benign skin tumors in mice and humans.";
RL   Hum. Mol. Genet. 14:1153-1160(2005).
RN   [61]
RP   VARIANT CATSHLS HIS-621.
RX   PubMed=17033969; DOI=10.1086/508433;
RA   Toydemir R.M., Brassington A.E., Bayrak-Toydemir P., Krakowiak P.A.,
RA   Jorde L.B., Whitby F.G., Longo N., Viskochil D.H., Carey J.C.,
RA   Bamshad M.J.;
RT   "A novel mutation in FGFR3 causes camptodactyly, tall stature, and hearing
RT   loss (CATSHL) syndrome.";
RL   Am. J. Hum. Genet. 79:935-941(2006).
RN   [62]
RP   VARIANTS KNEN CYS-248; CYS-370 AND ARG-380.
RX   PubMed=16841094; DOI=10.1172/jci28163;
RA   Hafner C., van Oers J.M.M., Vogt T., Landthaler M., Stoehr R., Blaszyk H.,
RA   Hofstaedter F., Zwarthoff E.C., Hartmann A.;
RT   "Mosaicism of activating FGFR3 mutations in human skin causes epidermal
RT   nevi.";
RL   J. Clin. Invest. 116:2201-2207(2006).
RN   [63]
RP   VARIANT LADDS ASN-513.
RX   PubMed=16501574; DOI=10.1038/ng1757;
RA   Rohmann E., Brunner H.G., Kayserili H., Uyguner O., Nuernberg G., Lew E.D.,
RA   Dobbie A., Eswarakumar V.P., Uzumcu A., Ulubil-Emeroglu M., Leroy J.G.,
RA   Li Y., Becker C., Lehnerdt K., Cremers C.W.R.J., Yueksel-Apak M.,
RA   Nuernberg P., Kubisch C., Schlessinger J., van Bokhoven H., Wollnik B.;
RT   "Mutations in different components of FGF signaling in LADD syndrome.";
RL   Nat. Genet. 38:414-417(2006).
RN   [64]
RP   VARIANT CAN GLU-391.
RX   PubMed=17935505; DOI=10.1111/j.1399-0004.2007.00884.x;
RA   Arnaud-Lopez L., Fragoso R., Mantilla-Capacho J., Barros-Nunez P.;
RT   "Crouzon with acanthosis nigricans. Further delineation of the syndrome.";
RL   Clin. Genet. 72:405-410(2007).
RN   [65]
RP   VARIANTS [LARGE SCALE ANALYSIS] SER-79; ARG-228; MET-338; LEU-384; ASN-646
RP   AND GLU-650.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [66]
RP   VARIANT TGCT GLU-650.
RX   PubMed=19855393; DOI=10.1038/ng.470;
RA   Goriely A., Hansen R.M., Taylor I.B., Olesen I.A., Jacobsen G.K.,
RA   McGowan S.J., Pfeifer S.P., McVean G.A., Rajpert-De Meyts E., Wilkie A.O.;
RT   "Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for
RT   congenital disorders and testicular tumors.";
RL   Nat. Genet. 41:1247-1252(2009).
CC   -!- FUNCTION: Tyrosine-protein kinase that acts as cell-surface receptor
CC       for fibroblast growth factors and plays an essential role in the
CC       regulation of cell proliferation, differentiation and apoptosis. Plays
CC       an essential role in the regulation of chondrocyte differentiation,
CC       proliferation and apoptosis, and is required for normal skeleton
CC       development. Regulates both osteogenesis and postnatal bone
CC       mineralization by osteoblasts. Promotes apoptosis in chondrocytes, but
CC       can also promote cancer cell proliferation. Required for normal
CC       development of the inner ear. Phosphorylates PLCG1, CBL and FRS2.
CC       Ligand binding leads to the activation of several signaling cascades.
CC       Activation of PLCG1 leads to the production of the cellular signaling
CC       molecules diacylglycerol and inositol 1,4,5-trisphosphate.
CC       Phosphorylation of FRS2 triggers recruitment of GRB2, GAB1, PIK3R1 and
CC       SOS1, and mediates activation of RAS, MAPK1/ERK2, MAPK3/ERK1 and the
CC       MAP kinase signaling pathway, as well as of the AKT1 signaling pathway.
CC       Plays a role in the regulation of vitamin D metabolism. Mutations that
CC       lead to constitutive kinase activation or impair normal FGFR3
CC       maturation, internalization and degradation lead to aberrant signaling.
CC       Over-expressed or constitutively activated FGFR3 promotes activation of
CC       PTPN11/SHP2, STAT1, STAT5A and STAT5B. Secreted isoform 3 retains its
CC       capacity to bind FGF1 and FGF2 and hence may interfere with FGF
CC       signaling. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:11294897,
CC       ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14534538,
CC       ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17311277,
CC       ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467,
CC       ECO:0000269|PubMed:19088846, ECO:0000269|PubMed:19286672,
CC       ECO:0000269|PubMed:8663044}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:17145761};
CC   -!- ACTIVITY REGULATION: Present in an inactive conformation in the absence
CC       of bound ligand. Ligand binding leads to dimerization and activation by
CC       autophosphorylation on tyrosine residues. Inhibited by SU5402.
CC       {ECO:0000269|PubMed:14732692, ECO:0000269|PubMed:17145761,
CC       ECO:0000269|PubMed:17509076}.
CC   -!- SUBUNIT: Monomer. Homodimer after ligand binding. Interacts with FGF1,
CC       FGF2, FGF4, FGF6; FGF8, FGF9, FGF10, FGF17, FGF18, FGF19, FGF20 and
CC       FGF23 (in vitro). Interacts with KLB. Affinity for fibroblast growth
CC       factors (FGFs) is increased by heparan sulfate glycosaminoglycans that
CC       function as coreceptors. Likewise, KLB increases the affinity for FGF19
CC       and FGF21. Interacts with PIK3R1, PLCG1, SOCS1 and SOCS3. Isoform 3
CC       forms disulfide-linked dimers. {ECO:0000269|PubMed:10611230,
CC       ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:14732692,
CC       ECO:0000269|PubMed:16410555, ECO:0000269|PubMed:16597617,
CC       ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:17623664,
CC       ECO:0000269|PubMed:19286672, ECO:0000269|PubMed:8663044}.
CC   -!- INTERACTION:
CC       P22607; Q6H8Q1-8: ABLIM2; NbExp=3; IntAct=EBI-348399, EBI-16436655;
CC       P22607; Q8NC06-3: ACBD4; NbExp=3; IntAct=EBI-348399, EBI-12811089;
CC       P22607; Q6UY14-3: ADAMTSL4; NbExp=3; IntAct=EBI-348399, EBI-10173507;
CC       P22607; Q8N302-2: AGGF1; NbExp=3; IntAct=EBI-348399, EBI-25838028;
CC       P22607; Q9UKV8: AGO2; NbExp=3; IntAct=EBI-348399, EBI-528269;
CC       P22607; P55008: AIF1; NbExp=3; IntAct=EBI-348399, EBI-9031341;
CC       P22607; Q99996-3: AKAP9; NbExp=3; IntAct=EBI-348399, EBI-11022349;
CC       P22607; Q9NQ31: AKIP1; NbExp=3; IntAct=EBI-348399, EBI-517035;
CC       P22607; P53677-2: AP3M2; NbExp=3; IntAct=EBI-348399, EBI-12177015;
CC       P22607; D3DTF8: APLN; NbExp=3; IntAct=EBI-348399, EBI-22002556;
CC       P22607; Q9NXL2-1: ARHGEF38; NbExp=3; IntAct=EBI-348399, EBI-18172597;
CC       P22607; Q9Y2Y0: ARL2BP; NbExp=3; IntAct=EBI-348399, EBI-3449344;
CC       P22607; Q66PJ3-4: ARL6IP4; NbExp=3; IntAct=EBI-348399, EBI-5280499;
CC       P22607; Q6XD76: ASCL4; NbExp=3; IntAct=EBI-348399, EBI-10254793;
CC       P22607; Q96FT7-4: ASIC4; NbExp=3; IntAct=EBI-348399, EBI-9089489;
CC       P22607; Q9UII2: ATP5IF1; NbExp=3; IntAct=EBI-348399, EBI-718459;
CC       P22607; Q9ULK2-2: ATXN7L1; NbExp=3; IntAct=EBI-348399, EBI-21568482;
CC       P22607; Q9H7T9: AUNIP; NbExp=3; IntAct=EBI-348399, EBI-10693257;
CC       P22607; Q8TBE0: BAHD1; NbExp=3; IntAct=EBI-348399, EBI-742750;
CC       P22607; Q9UQB8-6: BAIAP2; NbExp=3; IntAct=EBI-348399, EBI-9092016;
CC       P22607; Q16520: BATF; NbExp=3; IntAct=EBI-348399, EBI-749503;
CC       P22607; P54687-4: BCAT1; NbExp=3; IntAct=EBI-348399, EBI-25834445;
CC       P22607; Q00994: BEX3; NbExp=3; IntAct=EBI-348399, EBI-741753;
CC       P22607; Q5H9J7: BEX5; NbExp=3; IntAct=EBI-348399, EBI-10243741;
CC       P22607; Q9H2G9: BLZF1; NbExp=3; IntAct=EBI-348399, EBI-2548012;
CC       P22607; Q5PSV4: BRMS1L; NbExp=3; IntAct=EBI-348399, EBI-5666615;
CC       P22607; Q9ULD4-2: BRPF3; NbExp=3; IntAct=EBI-348399, EBI-23662416;
CC       P22607; Q9NSI6-4: BRWD1; NbExp=3; IntAct=EBI-348399, EBI-10693038;
CC       P22607; Q6P5X5: C22orf39; NbExp=3; IntAct=EBI-348399, EBI-7317823;
CC       P22607; Q3SXR2: C3orf36; NbExp=3; IntAct=EBI-348399, EBI-18036948;
CC       P22607; Q96LL4: C8orf48; NbExp=3; IntAct=EBI-348399, EBI-751596;
CC       P22607; P20807-4: CAPN3; NbExp=3; IntAct=EBI-348399, EBI-11532021;
CC       P22607; O00257-3: CBX4; NbExp=3; IntAct=EBI-348399, EBI-4392727;
CC       P22607; Q96HB5: CCDC120; NbExp=3; IntAct=EBI-348399, EBI-744556;
CC       P22607; Q6ZP82: CCDC141; NbExp=3; IntAct=EBI-348399, EBI-928795;
CC       P22607; Q5M9N0-2: CCDC158; NbExp=3; IntAct=EBI-348399, EBI-21796846;
CC       P22607; Q16543: CDC37; NbExp=3; IntAct=EBI-348399, EBI-295634;
CC       P22607; Q96GN5-2: CDCA7L; NbExp=3; IntAct=EBI-348399, EBI-9091443;
CC       P22607; P24941: CDK2; NbExp=3; IntAct=EBI-348399, EBI-375096;
CC       P22607; O14519: CDK2AP1; NbExp=3; IntAct=EBI-348399, EBI-1052532;
CC       P22607; P38936: CDKN1A; NbExp=3; IntAct=EBI-348399, EBI-375077;
CC       P22607; O95674: CDS2; NbExp=4; IntAct=EBI-348399, EBI-3913685;
CC       P22607; Q9H3R5: CENPH; NbExp=3; IntAct=EBI-348399, EBI-1003700;
CC       P22607; Q9Y4F5-3: CEP170B; NbExp=3; IntAct=EBI-348399, EBI-12950757;
CC       P22607; Q86XR8: CEP57; NbExp=3; IntAct=EBI-348399, EBI-308614;
CC       P22607; Q494V2-2: CFAP100; NbExp=3; IntAct=EBI-348399, EBI-11953200;
CC       P22607; Q8WUX9: CHMP7; NbExp=3; IntAct=EBI-348399, EBI-749253;
CC       P22607; Q9H2A9: CHST8; NbExp=3; IntAct=EBI-348399, EBI-21642354;
CC       P22607; Q9Y3D0: CIAO2B; NbExp=3; IntAct=EBI-348399, EBI-744045;
CC       P22607; Q96BR5: COA7; NbExp=3; IntAct=EBI-348399, EBI-6269632;
CC       P22607; P02458-1: COL2A1; NbExp=3; IntAct=EBI-348399, EBI-12375799;
CC       P22607; P21964-2: COMT; NbExp=3; IntAct=EBI-348399, EBI-10200977;
CC       P22607; Q86WV2: COX4I1; NbExp=3; IntAct=EBI-348399, EBI-10260134;
CC       P22607; Q03060-25: CREM; NbExp=3; IntAct=EBI-348399, EBI-12884642;
CC       P22607; Q8TB03: CXorf38; NbExp=3; IntAct=EBI-348399, EBI-12024320;
CC       P22607; O60759: CYTIP; NbExp=3; IntAct=EBI-348399, EBI-997814;
CC       P22607; Q9UJU6: DBNL; NbExp=3; IntAct=EBI-348399, EBI-751783;
CC       P22607; Q6ZN54-2: DEF8; NbExp=3; IntAct=EBI-348399, EBI-12346463;
CC       P22607; Q8NDP9: DKFZp547K2416; NbExp=3; IntAct=EBI-348399, EBI-25842538;
CC       P22607; O60479: DLX3; NbExp=3; IntAct=EBI-348399, EBI-3908248;
CC       P22607; Q96EY1-3: DNAJA3; NbExp=3; IntAct=EBI-348399, EBI-11526226;
CC       P22607; Q9H147: DNTTIP1; NbExp=3; IntAct=EBI-348399, EBI-2795449;
CC       P22607; Q92782-2: DPF1; NbExp=3; IntAct=EBI-348399, EBI-23669343;
CC       P22607; Q7Z7J5: DPPA2; NbExp=3; IntAct=EBI-348399, EBI-741400;
CC       P22607; Q14117: DPYS; NbExp=3; IntAct=EBI-348399, EBI-12275416;
CC       P22607; Q9BPU6: DPYSL5; NbExp=3; IntAct=EBI-348399, EBI-724653;
CC       P22607; Q9BVC3: DSCC1; NbExp=3; IntAct=EBI-348399, EBI-11143782;
CC       P22607; Q9Y6W6: DUSP10; NbExp=3; IntAct=EBI-348399, EBI-3443946;
CC       P22607; O14641: DVL2; NbExp=3; IntAct=EBI-348399, EBI-740850;
CC       P22607; A0AVK6: E2F8; NbExp=3; IntAct=EBI-348399, EBI-7779316;
CC       P22607; Q658K8: EEF1DP3; NbExp=3; IntAct=EBI-348399, EBI-10248874;
CC       P22607; Q6UXG2-3: ELAPOR1; NbExp=3; IntAct=EBI-348399, EBI-12920100;
CC       P22607; O00472: ELL2; NbExp=3; IntAct=EBI-348399, EBI-395274;
CC       P22607; O43768-8: ENSA; NbExp=3; IntAct=EBI-348399, EBI-25853109;
CC       P22607; Q6NXG1: ESRP1; NbExp=3; IntAct=EBI-348399, EBI-10213520;
CC       P22607; Q15910-2: EZH2; NbExp=3; IntAct=EBI-348399, EBI-10699473;
CC       P22607; Q96GL9: FAM163A; NbExp=3; IntAct=EBI-348399, EBI-11793142;
CC       P22607; A1KXE4-2: FAM168B; NbExp=3; IntAct=EBI-348399, EBI-12193763;
CC       P22607; Q8NB25: FAM184A; NbExp=3; IntAct=EBI-348399, EBI-9917523;
CC       P22607; Q86UY5: FAM83A; NbExp=3; IntAct=EBI-348399, EBI-1384254;
CC       P22607; Q8IZU1: FAM9A; NbExp=3; IntAct=EBI-348399, EBI-8468186;
CC       P22607; Q8TC84: FANK1; NbExp=3; IntAct=EBI-348399, EBI-21975404;
CC       P22607; Q9UBX5: FBLN5; NbExp=3; IntAct=EBI-348399, EBI-947897;
CC       P22607; Q9Y3I1: FBXO7; NbExp=3; IntAct=EBI-348399, EBI-1161222;
CC       P22607; O94868-3: FCHSD2; NbExp=3; IntAct=EBI-348399, EBI-11958845;
CC       P22607; P05230: FGF1; NbExp=3; IntAct=EBI-348399, EBI-698068;
CC       P22607; P22607: FGFR3; NbExp=4; IntAct=EBI-348399, EBI-348399;
CC       P22607; P15407: FOSL1; NbExp=3; IntAct=EBI-348399, EBI-744510;
CC       P22607; P15408: FOSL2; NbExp=3; IntAct=EBI-348399, EBI-3893419;
CC       P22607; P55318: FOXA3; NbExp=3; IntAct=EBI-348399, EBI-3910364;
CC       P22607; Q06547-2: GABPB1; NbExp=3; IntAct=EBI-348399, EBI-618189;
CC       P22607; Q06547-3: GABPB1; NbExp=3; IntAct=EBI-348399, EBI-9088619;
CC       P22607; P15976-2: GATA1; NbExp=3; IntAct=EBI-348399, EBI-9090198;
CC       P22607; P23769-2: GATA2; NbExp=3; IntAct=EBI-348399, EBI-21856389;
CC       P22607; P23771: GATA3; NbExp=3; IntAct=EBI-348399, EBI-6664760;
CC       P22607; Q49A26-4: GLYR1; NbExp=3; IntAct=EBI-348399, EBI-12143817;
CC       P22607; Q7Z5G4: GOLGA7; NbExp=3; IntAct=EBI-348399, EBI-4403685;
CC       P22607; Q9NWQ4-1: GPATCH2L; NbExp=3; IntAct=EBI-348399, EBI-11959863;
CC       P22607; P52655: GTF2A1; NbExp=3; IntAct=EBI-348399, EBI-389518;
CC       P22607; Q15486: GUSBP1; NbExp=4; IntAct=EBI-348399, EBI-712457;
CC       P22607; Q96CS2: HAUS1; NbExp=3; IntAct=EBI-348399, EBI-2514791;
CC       P22607; Q9BT25: HAUS8; NbExp=3; IntAct=EBI-348399, EBI-2558143;
CC       P22607; Q99075: HBEGF; NbExp=3; IntAct=EBI-348399, EBI-7211558;
CC       P22607; A8K0U2: hCG_2001421; NbExp=3; IntAct=EBI-348399, EBI-25843825;
CC       P22607; Q5T447-2: HECTD3; NbExp=3; IntAct=EBI-348399, EBI-25854793;
CC       P22607; Q8IV36: HID1; NbExp=3; IntAct=EBI-348399, EBI-743438;
CC       P22607; Q4VB01: HOXB1; NbExp=3; IntAct=EBI-348399, EBI-17494170;
CC       P22607; P09629: HOXB7; NbExp=3; IntAct=EBI-348399, EBI-1248457;
CC       P22607; O43248: HOXC11; NbExp=3; IntAct=EBI-348399, EBI-2652631;
CC       P22607; Q53T59: HS1BP3; NbExp=3; IntAct=EBI-348399, EBI-11335623;
CC       P22607; Q53GQ0: HSD17B12; NbExp=4; IntAct=EBI-348399, EBI-2963255;
CC       P22607; P14060: HSD3B1; NbExp=3; IntAct=EBI-348399, EBI-17426018;
CC       P22607; P08238: HSP90AB1; NbExp=4; IntAct=EBI-348399, EBI-352572;
CC       P22607; Q96EW2-2: HSPBAP1; NbExp=3; IntAct=EBI-348399, EBI-25835621;
CC       P22607; P10809: HSPD1; NbExp=3; IntAct=EBI-348399, EBI-352528;
CC       P22607; Q8NDH6-2: ICA1L; NbExp=3; IntAct=EBI-348399, EBI-12141931;
CC       P22607; P41134: ID1; NbExp=3; IntAct=EBI-348399, EBI-1215527;
CC       P22607; Q8IY31-2: IFT20; NbExp=3; IntAct=EBI-348399, EBI-11742277;
CC       P22607; P22692: IGFBP4; NbExp=3; IntAct=EBI-348399, EBI-2831948;
CC       P22607; Q9NZH6: IL37; NbExp=3; IntAct=EBI-348399, EBI-3862125;
CC       P22607; Q9NXX0: ILF3; NbExp=3; IntAct=EBI-348399, EBI-743980;
CC       P22607; Q86VI3: IQGAP3; NbExp=3; IntAct=EBI-348399, EBI-1237354;
CC       P22607; Q8NA54: IQUB; NbExp=3; IntAct=EBI-348399, EBI-10220600;
CC       P22607; Q86U28: ISCA2; NbExp=3; IntAct=EBI-348399, EBI-10258659;
CC       P22607; Q13352: ITGB3BP; NbExp=3; IntAct=EBI-348399, EBI-712105;
CC       P22607; P05412: JUN; NbExp=3; IntAct=EBI-348399, EBI-852823;
CC       P22607; P17275: JUNB; NbExp=3; IntAct=EBI-348399, EBI-748062;
CC       P22607; Q8N5Z5: KCTD17; NbExp=3; IntAct=EBI-348399, EBI-743960;
CC       P22607; Q7Z7F0-4: KHDC4; NbExp=3; IntAct=EBI-348399, EBI-9089060;
CC       P22607; Q9BVG8-5: KIFC3; NbExp=3; IntAct=EBI-348399, EBI-14069005;
CC       P22607; Q2M2Z5: KIZ; NbExp=3; IntAct=EBI-348399, EBI-2554344;
CC       P22607; Q6P597: KLC3; NbExp=3; IntAct=EBI-348399, EBI-1643885;
CC       P22607; P57682: KLF3; NbExp=3; IntAct=EBI-348399, EBI-8472267;
CC       P22607; Q9Y2M5: KLHL20; NbExp=3; IntAct=EBI-348399, EBI-714379;
CC       P22607; Q9UH77: KLHL3; NbExp=3; IntAct=EBI-348399, EBI-8524663;
CC       P22607; P08727: KRT19; NbExp=3; IntAct=EBI-348399, EBI-742756;
CC       P22607; Q14525: KRT33B; NbExp=3; IntAct=EBI-348399, EBI-1049638;
CC       P22607; Q3LI72: KRTAP19-5; NbExp=3; IntAct=EBI-348399, EBI-1048945;
CC       P22607; Q3SYF9: KRTAP19-7; NbExp=3; IntAct=EBI-348399, EBI-10241353;
CC       P22607; Q8IUC2: KRTAP8-1; NbExp=3; IntAct=EBI-348399, EBI-10261141;
CC       P22607; Q6IAA8: LAMTOR1; NbExp=3; IntAct=EBI-348399, EBI-715385;
CC       P22607; A0A0C4DGV4: LAMTOR5; NbExp=3; IntAct=EBI-348399, EBI-10173304;
CC       P22607; Q14847-2: LASP1; NbExp=3; IntAct=EBI-348399, EBI-9088686;
CC       P22607; Q9H2C1: LHX5; NbExp=3; IntAct=EBI-348399, EBI-25835523;
CC       P22607; Q68G74: LHX8; NbExp=3; IntAct=EBI-348399, EBI-8474075;
CC       P22607; Q8N0U6: LINC00518; NbExp=3; IntAct=EBI-348399, EBI-10264791;
CC       P22607; Q1L5Z9: LONRF2; NbExp=3; IntAct=EBI-348399, EBI-2510853;
CC       P22607; Q96JB6: LOXL4; NbExp=3; IntAct=EBI-348399, EBI-749562;
CC       P22607; Q96LR2: LURAP1; NbExp=3; IntAct=EBI-348399, EBI-741355;
CC       P22607; P0DP58-2: LYNX1; NbExp=3; IntAct=EBI-348399, EBI-21916939;
CC       P22607; P27338: MAOB; NbExp=3; IntAct=EBI-348399, EBI-3911344;
CC       P22607; Q9GZQ8: MAP1LC3B; NbExp=3; IntAct=EBI-348399, EBI-373144;
CC       P22607; Q15759: MAPK11; NbExp=3; IntAct=EBI-348399, EBI-298304;
CC       P22607; Q9NS73-5: MBIP; NbExp=3; IntAct=EBI-348399, EBI-10182361;
CC       P22607; P33993-2: MCM7; NbExp=3; IntAct=EBI-348399, EBI-11741465;
CC       P22607; Q96EZ8: MCRS1; NbExp=3; IntAct=EBI-348399, EBI-348259;
CC       P22607; Q9HAF1: MEAF6; NbExp=3; IntAct=EBI-348399, EBI-399266;
CC       P22607; Q9H8H3: METTL7A; NbExp=3; IntAct=EBI-348399, EBI-1390168;
CC       P22607; D3DX41: MGC16703; NbExp=3; IntAct=EBI-348399, EBI-25850974;
CC       P22607; Q8TAC0: MGC27345; NbExp=3; IntAct=EBI-348399, EBI-25851300;
CC       P22607; Q53S70: MGC4677; NbExp=3; IntAct=EBI-348399, EBI-10242717;
CC       P22607; Q5JXC2: MIIP; NbExp=3; IntAct=EBI-348399, EBI-2801965;
CC       P22607; A0A0A0MR05: MLST8; NbExp=3; IntAct=EBI-348399, EBI-25835557;
CC       P22607; Q00013: MPP1; NbExp=3; IntAct=EBI-348399, EBI-711788;
CC       P22607; Q8TCY5: MRAP; NbExp=3; IntAct=EBI-348399, EBI-9538727;
CC       P22607; Q6IN84-2: MRM1; NbExp=3; IntAct=EBI-348399, EBI-25835707;
CC       P22607; O60783: MRPS14; NbExp=3; IntAct=EBI-348399, EBI-1045956;
CC       P22607; Q96H12: MSANTD3; NbExp=3; IntAct=EBI-348399, EBI-8466227;
CC       P22607; P01106: MYC; NbExp=3; IntAct=EBI-348399, EBI-447544;
CC       P22607; Q9NPC6: MYOZ2; NbExp=3; IntAct=EBI-348399, EBI-746712;
CC       P22607; P41271-2: NBL1; NbExp=3; IntAct=EBI-348399, EBI-12135485;
CC       P22607; P14598: NCF1; NbExp=3; IntAct=EBI-348399, EBI-395044;
CC       P22607; Q9GZM8: NDEL1; NbExp=3; IntAct=EBI-348399, EBI-928842;
CC       P22607; Q8NC67-2: NETO2; NbExp=3; IntAct=EBI-348399, EBI-25852289;
CC       P22607; Q16621: NFE2; NbExp=3; IntAct=EBI-348399, EBI-726369;
CC       P22607; Q8N5V2: NGEF; NbExp=3; IntAct=EBI-348399, EBI-718372;
CC       P22607; Q99743: NPAS2; NbExp=3; IntAct=EBI-348399, EBI-3932727;
CC       P22607; Q14995: NR1D2; NbExp=3; IntAct=EBI-348399, EBI-6144053;
CC       P22607; F1D8P7: NR1H2; NbExp=3; IntAct=EBI-348399, EBI-10177172;
CC       P22607; Q6PHZ7: NR2C2; NbExp=3; IntAct=EBI-348399, EBI-2802743;
CC       P22607; Q9BZ95-3: NSD3; NbExp=3; IntAct=EBI-348399, EBI-22002759;
CC       P22607; Q96MF7: NSMCE2; NbExp=3; IntAct=EBI-348399, EBI-2557388;
CC       P22607; Q4KMX9: OBSCN; NbExp=3; IntAct=EBI-348399, EBI-10490715;
CC       P22607; A5D8V7: ODAD3; NbExp=3; IntAct=EBI-348399, EBI-8466445;
CC       P22607; Q5BJF6-2: ODF2; NbExp=3; IntAct=EBI-348399, EBI-9090919;
CC       P22607; Q3SX64: ODF3L2; NbExp=3; IntAct=EBI-348399, EBI-6660184;
CC       P22607; O43482: OIP5; NbExp=3; IntAct=EBI-348399, EBI-536879;
CC       P22607; Q6GQQ9-2: OTUD7B; NbExp=3; IntAct=EBI-348399, EBI-25830200;
CC       P22607; Q8IVL6-2: P3H3; NbExp=3; IntAct=EBI-348399, EBI-12149899;
CC       P22607; Q9H8K7: PAAT; NbExp=3; IntAct=EBI-348399, EBI-714785;
CC       P22607; Q8N3R9: PALS1; NbExp=3; IntAct=EBI-348399, EBI-2513978;
CC       P22607; Q495U3: PANX2; NbExp=3; IntAct=EBI-348399, EBI-17242559;
CC       P22607; Q9NR21-5: PARP11; NbExp=3; IntAct=EBI-348399, EBI-17159452;
CC       P22607; Q9BR81: PCDHGC3; NbExp=3; IntAct=EBI-348399, EBI-22012354;
CC       P22607; Q5VU43-8: PDE4DIP; NbExp=3; IntAct=EBI-348399, EBI-25837868;
CC       P22607; Q13956: PDE6H; NbExp=3; IntAct=EBI-348399, EBI-10231995;
CC       P22607; O15534: PER1; NbExp=3; IntAct=EBI-348399, EBI-2557276;
CC       P22607; O15212: PFDN6; NbExp=3; IntAct=EBI-348399, EBI-356973;
CC       P22607; Q9BUL5: PHF23; NbExp=3; IntAct=EBI-348399, EBI-722852;
CC       P22607; P14618: PKM; NbExp=3; IntAct=EBI-348399, EBI-353408;
CC       P22607; Q9UPR0: PLCL2; NbExp=3; IntAct=EBI-348399, EBI-311059;
CC       P22607; Q6ZR37: PLEKHG7; NbExp=3; IntAct=EBI-348399, EBI-12891828;
CC       P22607; Q5SXH7-1: PLEKHS1; NbExp=3; IntAct=EBI-348399, EBI-26412802;
CC       P22607; Q96T60: PNKP; NbExp=3; IntAct=EBI-348399, EBI-1045072;
CC       P22607; P19388: POLR2E; NbExp=3; IntAct=EBI-348399, EBI-395189;
CC       P22607; Q07869: PPARA; NbExp=3; IntAct=EBI-348399, EBI-78615;
CC       P22607; Q9UNP9: PPIE; NbExp=3; IntAct=EBI-348399, EBI-591818;
CC       P22607; O60927: PPP1R11; NbExp=3; IntAct=EBI-348399, EBI-1048104;
CC       P22607; O60237-2: PPP1R12B; NbExp=3; IntAct=EBI-348399, EBI-10700351;
CC       P22607; Q96I34: PPP1R16A; NbExp=3; IntAct=EBI-348399, EBI-710402;
CC       P22607; Q6ZMI0-5: PPP1R21; NbExp=3; IntAct=EBI-348399, EBI-25835994;
CC       P22607; O43741: PRKAB2; NbExp=3; IntAct=EBI-348399, EBI-1053424;
CC       P22607; O60260-5: PRKN; NbExp=3; IntAct=EBI-348399, EBI-21251460;
CC       P22607; Q86UA1: PRPF39; NbExp=3; IntAct=EBI-348399, EBI-2803203;
CC       P22607; P62333: PSMC6; NbExp=3; IntAct=EBI-348399, EBI-357669;
CC       P22607; Q06323: PSME1; NbExp=3; IntAct=EBI-348399, EBI-712149;
CC       P22607; P06454-2: PTMA; NbExp=3; IntAct=EBI-348399, EBI-10194874;
CC       P22607; Q8WUD1-2: RAB2B; NbExp=3; IntAct=EBI-348399, EBI-25835884;
CC       P22607; Q9UNT1-2: RABL2B; NbExp=3; IntAct=EBI-348399, EBI-12256104;
CC       P22607; Q15311: RALBP1; NbExp=3; IntAct=EBI-348399, EBI-749285;
CC       P22607; Q9HD47-3: RANGRF; NbExp=3; IntAct=EBI-348399, EBI-9089733;
CC       P22607; Q9NS23-4: RASSF1; NbExp=3; IntAct=EBI-348399, EBI-438710;
CC       P22607; Q9NWB1-5: RBFOX1; NbExp=3; IntAct=EBI-348399, EBI-12123390;
CC       P22607; Q9BWF3: RBM4; NbExp=3; IntAct=EBI-348399, EBI-2856454;
CC       P22607; Q8TBY0: RBM46; NbExp=3; IntAct=EBI-348399, EBI-12068216;
CC       P22607; Q9P2K3-2: RCOR3; NbExp=3; IntAct=EBI-348399, EBI-1504830;
CC       P22607; Q04206: RELA; NbExp=3; IntAct=EBI-348399, EBI-73886;
CC       P22607; P47804-3: RGR; NbExp=3; IntAct=EBI-348399, EBI-25834767;
CC       P22607; Q15382: RHEB; NbExp=3; IntAct=EBI-348399, EBI-1055287;
CC       P22607; Q8IXN7: RIMKLA; NbExp=3; IntAct=EBI-348399, EBI-21890191;
CC       P22607; Q8WVD3: RNF138; NbExp=3; IntAct=EBI-348399, EBI-749039;
CC       P22607; Q9H0X6: RNF208; NbExp=3; IntAct=EBI-348399, EBI-751555;
CC       P22607; P62899: RPL31; NbExp=3; IntAct=EBI-348399, EBI-1053664;
CC       P22607; P62244: RPS15A; NbExp=3; IntAct=EBI-348399, EBI-347895;
CC       P22607; P62701: RPS4X; NbExp=3; IntAct=EBI-348399, EBI-354303;
CC       P22607; Q66K80: RUSC1-AS1; NbExp=3; IntAct=EBI-348399, EBI-10248967;
CC       P22607; Q9BY12-3: SCAPER; NbExp=3; IntAct=EBI-348399, EBI-25837959;
CC       P22607; Q86SQ7-2: SDCCAG8; NbExp=3; IntAct=EBI-348399, EBI-10696955;
CC       P22607; Q9NTN9-3: SEMA4G; NbExp=3; IntAct=EBI-348399, EBI-9089805;
CC       P22607; Q13435: SF3B2; NbExp=3; IntAct=EBI-348399, EBI-749111;
CC       P22607; O60902-3: SHOX2; NbExp=3; IntAct=EBI-348399, EBI-9092164;
CC       P22607; Q9NSD5-3: SLC6A13; NbExp=3; IntAct=EBI-348399, EBI-25831241;
CC       P22607; Q9UHI5: SLC7A8; NbExp=3; IntAct=EBI-348399, EBI-13292283;
CC       P22607; Q12824: SMARCB1; NbExp=3; IntAct=EBI-348399, EBI-358419;
CC       P22607; Q13573: SNW1; NbExp=3; IntAct=EBI-348399, EBI-632715;
CC       P22607; O14544: SOCS6; NbExp=3; IntAct=EBI-348399, EBI-3929549;
CC       P22607; Q02086-2: SP2; NbExp=3; IntAct=EBI-348399, EBI-9088579;
CC       P22607; Q7Z6I5: SPATA12; NbExp=3; IntAct=EBI-348399, EBI-10696971;
CC       P22607; Q86W54-2: SPATA24; NbExp=3; IntAct=EBI-348399, EBI-12041693;
CC       P22607; Q496A3: SPATS1; NbExp=3; IntAct=EBI-348399, EBI-3923692;
CC       P22607; Q7Z698: SPRED2; NbExp=3; IntAct=EBI-348399, EBI-7082156;
CC       P22607; Q9C004: SPRY4; NbExp=3; IntAct=EBI-348399, EBI-354861;
CC       P22607; Q5W111-2: SPRYD7; NbExp=3; IntAct=EBI-348399, EBI-12408727;
CC       P22607; Q99469: STAC; NbExp=3; IntAct=EBI-348399, EBI-2652799;
CC       P22607; Q92783-2: STAM; NbExp=3; IntAct=EBI-348399, EBI-12025738;
CC       P22607; O75886: STAM2; NbExp=3; IntAct=EBI-348399, EBI-373258;
CC       P22607; Q13586: STIM1; NbExp=4; IntAct=EBI-348399, EBI-448878;
CC       P22607; Q8N4C7: STX19; NbExp=3; IntAct=EBI-348399, EBI-8484990;
CC       P22607; Q15814: TBCC; NbExp=3; IntAct=EBI-348399, EBI-15695297;
CC       P22607; O15273: TCAP; NbExp=3; IntAct=EBI-348399, EBI-954089;
CC       P22607; Q86WV5: TEN1; NbExp=3; IntAct=EBI-348399, EBI-2562799;
CC       P22607; Q96A09: TENT5B; NbExp=3; IntAct=EBI-348399, EBI-752030;
CC       P22607; P54274-2: TERF1; NbExp=3; IntAct=EBI-348399, EBI-711018;
CC       P22607; Q6N021: TET2; NbExp=3; IntAct=EBI-348399, EBI-310727;
CC       P22607; Q9BXU0: TEX12; NbExp=3; IntAct=EBI-348399, EBI-12090309;
CC       P22607; Q5T0J7-2: TEX35; NbExp=3; IntAct=EBI-348399, EBI-12833746;
CC       P22607; Q8WTV1: THAP3; NbExp=3; IntAct=EBI-348399, EBI-17438286;
CC       P22607; Q5T1C6: THEM4; NbExp=3; IntAct=EBI-348399, EBI-7684443;
CC       P22607; O60830: TIMM17B; NbExp=3; IntAct=EBI-348399, EBI-2372529;
CC       P22607; Q9BZW5-2: TM6SF1; NbExp=3; IntAct=EBI-348399, EBI-25852210;
CC       P22607; Q96B77: TMEM186; NbExp=3; IntAct=EBI-348399, EBI-9089409;
CC       P22607; Q8N0U2: TMEM61; NbExp=3; IntAct=EBI-348399, EBI-25830583;
CC       P22607; Q53NU3: tmp_locus_54; NbExp=3; IntAct=EBI-348399, EBI-10242677;
CC       P22607; Q8IUR5-4: TMTC1; NbExp=3; IntAct=EBI-348399, EBI-9089156;
CC       P22607; Q71RG4-4: TMUB2; NbExp=3; IntAct=EBI-348399, EBI-25831574;
CC       P22607; P50616: TOB1; NbExp=3; IntAct=EBI-348399, EBI-723281;
CC       P22607; Q9H496: TOR1AIP2; NbExp=3; IntAct=EBI-348399, EBI-2510146;
CC       P22607; P36406: TRIM23; NbExp=3; IntAct=EBI-348399, EBI-740098;
CC       P22607; Q9UPQ4-2: TRIM35; NbExp=3; IntAct=EBI-348399, EBI-17716262;
CC       P22607; Q86WT6-2: TRIM69; NbExp=3; IntAct=EBI-348399, EBI-11525489;
CC       P22607; Q9Y3Q8: TSC22D4; NbExp=3; IntAct=EBI-348399, EBI-739485;
CC       P22607; Q99598: TSNAX; NbExp=3; IntAct=EBI-348399, EBI-742638;
CC       P22607; O60636: TSPAN2; NbExp=3; IntAct=EBI-348399, EBI-3914288;
CC       P22607; Q6PF05: TTC23L; NbExp=3; IntAct=EBI-348399, EBI-8656864;
CC       P22607; Q9UGJ1-2: TUBGCP4; NbExp=3; IntAct=EBI-348399, EBI-10964469;
CC       P22607; P49459: UBE2A; NbExp=3; IntAct=EBI-348399, EBI-2339348;
CC       P22607; Q13404: UBE2V1; NbExp=3; IntAct=EBI-348399, EBI-1050671;
CC       P22607; P11441: UBL4A; NbExp=3; IntAct=EBI-348399, EBI-356983;
CC       P22607; Q9HA47-2: UCK1; NbExp=3; IntAct=EBI-348399, EBI-16434682;
CC       P22607; P22415: USF1; NbExp=3; IntAct=EBI-348399, EBI-1054489;
CC       P22607; Q495M9: USH1G; NbExp=3; IntAct=EBI-348399, EBI-8601749;
CC       P22607; Q9H270: VPS11; NbExp=3; IntAct=EBI-348399, EBI-373380;
CC       P22607; Q8NEZ2: VPS37A; NbExp=3; IntAct=EBI-348399, EBI-2850578;
CC       P22607; Q9P1Q0-4: VPS54; NbExp=3; IntAct=EBI-348399, EBI-25835297;
CC       P22607; Q9NX94: WBP1L; NbExp=3; IntAct=EBI-348399, EBI-10316321;
CC       P22607; Q8TBZ3-3: WDR20; NbExp=3; IntAct=EBI-348399, EBI-9089370;
CC       P22607; O00755: WNT7A; NbExp=3; IntAct=EBI-348399, EBI-727198;
CC       P22607; P19544-6: WT1; NbExp=3; IntAct=EBI-348399, EBI-11745701;
CC       P22607; O43829: ZBTB14; NbExp=3; IntAct=EBI-348399, EBI-10176632;
CC       P22607; Q53FD0-2: ZC2HC1C; NbExp=3; IntAct=EBI-348399, EBI-14104088;
CC       P22607; Q9NP64: ZCCHC17; NbExp=3; IntAct=EBI-348399, EBI-746345;
CC       P22607; Q8WUU4: ZNF296; NbExp=3; IntAct=EBI-348399, EBI-8834821;
CC       P22607; Q96JL9-2: ZNF333; NbExp=3; IntAct=EBI-348399, EBI-25835852;
CC       P22607; Q9C0F3: ZNF436; NbExp=3; IntAct=EBI-348399, EBI-8489702;
CC       P22607; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-348399, EBI-745520;
CC       P22607; Q3KNS6-3: ZNF829; NbExp=3; IntAct=EBI-348399, EBI-18036029;
CC       P22607; B7Z3E8; NbExp=3; IntAct=EBI-348399, EBI-25831617;
CC       P22607; Q7L8T7; NbExp=3; IntAct=EBI-348399, EBI-25831943;
CC       P22607; Q7Z637; NbExp=3; IntAct=EBI-348399, EBI-25831475;
CC       P22607; Q86V28; NbExp=3; IntAct=EBI-348399, EBI-10259496;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Cell membrane; Single-pass type I
CC       membrane protein. Cytoplasmic vesicle. Endoplasmic reticulum. Note=The
CC       activated receptor is rapidly internalized and degraded. Detected in
CC       intracellular vesicles after internalization of the autophosphorylated
CC       receptor.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cell membrane {ECO:0000250}; Single-
CC       pass type I membrane protein {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: [Isoform 3]: Secreted.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Cell membrane {ECO:0000250}; Single-
CC       pass type I membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=IIIc;
CC         IsoId=P22607-1; Sequence=Displayed;
CC       Name=2; Synonyms=IIIb;
CC         IsoId=P22607-2; Sequence=VSP_002988;
CC       Name=3; Synonyms=FGFR3deltaTM;
CC         IsoId=P22607-3; Sequence=VSP_002989;
CC       Name=4;
CC         IsoId=P22607-4; Sequence=VSP_040945;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, kidney and testis. Very low or
CC       no expression in spleen, heart, and muscle. In 20- to 22-week old
CC       fetuses it is expressed at high level in kidney, lung, small intestine
CC       and brain, and to a lower degree in spleen, liver, and muscle. Isoform
CC       2 is detected in epithelial cells. Isoform 1 is not detected in
CC       epithelial cells. Isoform 1 and isoform 2 are detected in fibroblastic
CC       cells. {ECO:0000269|PubMed:1664411}.
CC   -!- DOMAIN: The second and third Ig-like domains directly interact with
CC       fibroblast growth factors (FGF) and heparan sulfate proteoglycans.
CC       {ECO:0000269|PubMed:14732692}.
CC   -!- PTM: Autophosphorylated. Binding of FGF family members together with
CC       heparan sulfate proteoglycan or heparin promotes receptor dimerization
CC       and autophosphorylation on tyrosine residues. Autophosphorylation
CC       occurs in trans between the two FGFR molecules present in the dimer.
CC       Phosphorylation at Tyr-724 is essential for stimulation of cell
CC       proliferation and activation of PIK3R1, STAT1 and MAP kinase signaling.
CC       Phosphorylation at Tyr-760 is required for interaction with PIK3R1 and
CC       PLCG1. {ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:19286672}.
CC   -!- PTM: Ubiquitinated. Is rapidly ubiquitinated after ligand binding and
CC       autophosphorylation, leading to receptor internalization and
CC       degradation. Subject to both proteasomal and lysosomal degradation.
CC       {ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:17509076}.
CC   -!- PTM: N-glycosylated in the endoplasmic reticulum. The N-glycan chains
CC       undergo further maturation to an Endo H-resistant form in the Golgi
CC       apparatus. {ECO:0000269|PubMed:11703096, ECO:0000269|PubMed:16410555,
CC       ECO:0000269|PubMed:17311277, ECO:0000269|PubMed:17509076}.
CC   -!- DISEASE: Achondroplasia (ACH) [MIM:100800]: A frequent form of short-
CC       limb dwarfism. It is characterized by a long, narrow trunk, short
CC       extremities, particularly in the proximal (rhizomelic) segments, a
CC       large head with frontal bossing, hypoplasia of the midface and a
CC       trident configuration of the hands. ACH is an autosomal dominant
CC       disease. {ECO:0000269|PubMed:10611230, ECO:0000269|PubMed:12297284,
CC       ECO:0000269|PubMed:7758520, ECO:0000269|PubMed:7847369,
CC       ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Crouzon syndrome with acanthosis nigricans (CAN) [MIM:612247]:
CC       Classic Crouzon disease which is caused by mutations in the FGFR2 gene
CC       is characterized by craniosynostosis (premature fusion of the skull
CC       sutures), and facial hypoplasia. Crouzon syndrome with acanthosis
CC       nigricans (a skin disorder characterized by pigmentation anomalies),
CC       CAN, is considered to be an independent disorder from classic Crouzon
CC       syndrome. CAN is characterized by additional more severe physical
CC       manifestation, such as Chiari malformation, hydrocephalus, and atresia
CC       or stenosis of the choanas, and is caused by a specific mutation (Ala-
CC       391 to Glu) in the transmembrane domain of FGFR3. It is proposed to
CC       have an autosomal dominant mode of inheritance.
CC       {ECO:0000269|PubMed:17935505, ECO:0000269|PubMed:7493034}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Thanatophoric dysplasia 1 (TD1) [MIM:187600]: A neonatal
CC       lethal skeletal dysplasia. Affected individuals manifest severe
CC       shortening of the limbs with macrocephaly, narrow thorax, short ribs,
CC       and curved femurs. {ECO:0000269|PubMed:10360402,
CC       ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:7773297,
CC       ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844,
CC       ECO:0000269|PubMed:9790257}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Thanatophoric dysplasia 2 (TD2) [MIM:187601]: A neonatal
CC       lethal skeletal dysplasia causing severe shortening of the limbs,
CC       narrow thorax and short ribs. Patients with thanatophoric dysplasia
CC       type 2 have straight femurs and cloverleaf skull.
CC       {ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:7773297,
CC       ECO:0000269|PubMed:8754806}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Hypochondroplasia (HCH) [MIM:146000]: Autosomal dominant
CC       disease and is characterized by disproportionate short stature. It
CC       resembles achondroplasia, but with a less severe phenotype.
CC       {ECO:0000269|PubMed:10215410, ECO:0000269|PubMed:10777366,
CC       ECO:0000269|PubMed:11055896, ECO:0000269|PubMed:12707965,
CC       ECO:0000269|PubMed:7670477, ECO:0000269|PubMed:9452043}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Bladder cancer (BLC) [MIM:109800]: A malignancy originating in
CC       tissues of the urinary bladder. It often presents with multiple tumors
CC       appearing at different times and at different sites in the bladder.
CC       Most bladder cancers are transitional cell carcinomas that begin in
CC       cells that normally make up the inner lining of the bladder. Other
CC       types of bladder cancer include squamous cell carcinoma (cancer that
CC       begins in thin, flat cells) and adenocarcinoma (cancer that begins in
CC       cells that make and release mucus and other fluids). Bladder cancer is
CC       a complex disorder with both genetic and environmental influences.
CC       {ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11314002}.
CC       Note=Disease susceptibility is associated with variants affecting the
CC       gene represented in this entry. Somatic mutations can constitutively
CC       activate FGFR3.
CC   -!- DISEASE: Cervical cancer (CERCA) [MIM:603956]: A malignant neoplasm of
CC       the cervix, typically originating from a dysplastic or premalignant
CC       lesion previously present at the active squamocolumnar junction. The
CC       transformation from mild dysplastic to invasive carcinoma generally
CC       occurs slowly within several years, although the rate of this process
CC       varies widely. Carcinoma in situ is particularly known to precede
CC       invasive cervical cancer in most cases. Cervical cancer is strongly
CC       associated with infection by oncogenic types of human papillomavirus.
CC       {ECO:0000269|PubMed:10471491}. Note=The gene represented in this entry
CC       is involved in disease pathogenesis.
CC   -!- DISEASE: Camptodactyly, tall stature, and hearing loss syndrome
CC       (CATSHLS) [MIM:610474]: An autosomal dominant syndrome characterized by
CC       permanent and irreducible flexion of one or more fingers of the hand
CC       and/or feet, tall stature, scoliosis and/or a pectus excavatum, and
CC       hearing loss. Affected individuals have developmental delay and/or
CC       intellectual disability, and several of these have microcephaly.
CC       Radiographic findings included tall vertebral bodies with irregular
CC       borders and broad femoral metaphyses with long tubular shafts. On
CC       audiological exam, each tested member have bilateral sensorineural
CC       hearing loss and absent otoacoustic emissions. The hearing loss was
CC       congenital or developed in early infancy, progressed variably in early
CC       childhood, and range from mild to severe. Computed tomography and
CC       magnetic resonance imaging reveal that the brain, middle ear, and inner
CC       ear are structurally normal. {ECO:0000269|PubMed:17033969}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Multiple myeloma (MM) [MIM:254500]: A malignant tumor of
CC       plasma cells usually arising in the bone marrow and characterized by
CC       diffuse involvement of the skeletal system, hyperglobulinemia, Bence-
CC       Jones proteinuria and anemia. Complications of multiple myeloma are
CC       bone pain, hypercalcemia, renal failure and spinal cord compression.
CC       The aberrant antibodies that are produced lead to impaired humoral
CC       immunity and patients have a high prevalence of infection. Amyloidosis
CC       may develop in some patients. Multiple myeloma is part of a spectrum of
CC       diseases ranging from monoclonal gammopathy of unknown significance
CC       (MGUS) to plasma cell leukemia. {ECO:0000269|PubMed:11529856,
CC       ECO:0000269|PubMed:9207791}. Note=The gene represented in this entry
CC       may be involved in disease pathogenesis. A chromosomal aberration
CC       involving FGFR3 is found in multiple myeloma. Translocation
CC       t(4;14)(p16.3;q32.3) with the IgH locus.
CC   -!- DISEASE: Lacrimo-auriculo-dento-digital syndrome (LADDS) [MIM:149730]:
CC       An autosomal dominant ectodermal dysplasia, a heterogeneous group of
CC       disorders due to abnormal development of two or more ectodermal
CC       structures. Lacrimo-auriculo-dento-digital syndrome is characterized by
CC       aplastic/hypoplastic lacrimal and salivary glands and ducts, cup-shaped
CC       ears, hearing loss, hypodontia and enamel hypoplasia, and distal limb
CC       segments anomalies. In addition to these cardinal features, facial
CC       dysmorphism, malformations of the kidney and respiratory system and
CC       abnormal genitalia have been reported. Craniosynostosis and severe
CC       syndactyly are not observed. {ECO:0000269|PubMed:16501574}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Keratinocytic non-epidermolytic nevus (KNEN) [MIM:162900]:
CC       Epidermal nevi of the common, non-organoid and non-epidermolytic type
CC       are benign skin lesions and may vary in their extent from a single
CC       (usually linear) lesion to widespread and systematized involvement.
CC       They may be present at birth or develop early during childhood.
CC       {ECO:0000269|PubMed:16841094}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Muenke syndrome (MNKS) [MIM:602849]: A condition characterized
CC       by premature closure of coronal suture of skull during development
CC       (coronal craniosynostosis), which affects the shape of the head and
CC       face. It may be uni- or bilateral. When bilateral, it is characterized
CC       by a skull with a small antero-posterior diameter (brachycephaly),
CC       often with a decrease in the depth of the orbits and hypoplasia of the
CC       maxillae. Unilateral closure of the coronal sutures leads to flattening
CC       of the orbit on the involved side (plagiocephaly). The intellect is
CC       normal. In addition to coronal craniosynostosis some affected
CC       individuals show skeletal abnormalities of hands and feet,
CC       sensorineural hearing loss, intellectual disability and respiratory
CC       insufficiency. {ECO:0000269|PubMed:11746040,
CC       ECO:0000269|PubMed:9042914, ECO:0000269|PubMed:9950359}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Keratosis, seborrheic (KERSEB) [MIM:182000]: A common benign
CC       skin tumor. Seborrheic keratoses usually begin with the appearance of
CC       one or more sharply defined, light brown, flat macules. The lesions may
CC       be sparse or numerous. As they initially grow, they develop a velvety
CC       to finely verrucous surface, followed by an uneven warty surface with
CC       multiple plugged follicles and a dull or lackluster appearance.
CC       {ECO:0000269|PubMed:15772091}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Testicular germ cell tumor (TGCT) [MIM:273300]: A common
CC       malignancy in males representing 95% of all testicular neoplasms. TGCTs
CC       have various pathologic subtypes including: unclassified intratubular
CC       germ cell neoplasia, seminoma (including cases with
CC       syncytiotrophoblastic cells), spermatocytic seminoma, embryonal
CC       carcinoma, yolk sac tumor, choriocarcinoma, and teratoma.
CC       {ECO:0000269|PubMed:19855393}. Note=The gene represented in this entry
CC       may be involved in disease pathogenesis.
CC   -!- DISEASE: Achondroplasia, severe, with developmental delay and
CC       acanthosis nigricans (SADDAN) [MIM:616482]: A severe form of
CC       achondroplasia associated with developmental delay and acanthosis
CC       nigricans. Patients manifest short-limb dwarfism, with a long, narrow
CC       trunk, short extremities, particularly in the proximal (rhizomelic)
CC       segments, a large head with frontal bossing, hypoplasia of the midface
CC       and a trident configuration of the hands. Acanthosis nigricans is a
CC       skin condition characterized by brown-pigmented, velvety verrucosities
CC       in body folds and creases. {ECO:0000269|PubMed:10053006}. Note=The
CC       disease is caused by variants affecting the gene represented in this
CC       entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Fibroblast growth factor receptor subfamily.
CC       {ECO:0000255|PROSITE-ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAD92678.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/FGFRID99.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/fgfr3/";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M58051; AAA52450.1; -; mRNA.
DR   EMBL; AF245114; AAF63380.1; -; mRNA.
DR   EMBL; AB209441; BAD92678.1; ALT_INIT; mRNA.
DR   EMBL; AY768549; AAU89726.1; -; Genomic_DNA.
DR   EMBL; AC016773; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471131; EAW82564.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82565.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82566.1; -; Genomic_DNA.
DR   EMBL; CH471131; EAW82567.1; -; Genomic_DNA.
DR   EMBL; M64347; AAA58470.1; -; mRNA.
DR   EMBL; M59374; AAA63209.1; -; mRNA.
DR   EMBL; S76733; AAB33323.1; -; Genomic_DNA.
DR   EMBL; X84939; CAA59334.1; -; mRNA.
DR   EMBL; U22410; AAA67781.1; -; Genomic_DNA.
DR   CCDS; CCDS3353.1; -. [P22607-1]
DR   CCDS; CCDS3354.1; -. [P22607-3]
DR   CCDS; CCDS54706.1; -. [P22607-2]
DR   PIR; A38576; TVHUF3.
DR   RefSeq; NP_000133.1; NM_000142.4. [P22607-1]
DR   RefSeq; NP_001156685.1; NM_001163213.1. [P22607-2]
DR   RefSeq; NP_075254.1; NM_022965.3. [P22607-3]
DR   PDB; 1RY7; X-ray; 3.20 A; B=33-365.
DR   PDB; 2LZL; NMR; -; A/B=357-399.
DR   PDB; 4K33; X-ray; 2.34 A; A=449-759.
DR   PDB; 6LVM; X-ray; 2.53 A; A=472-759.
DR   PDB; 6PNX; X-ray; 2.20 A; A/B=451-759.
DR   PDB; 7DHL; X-ray; 2.57 A; A=472-759.
DR   PDBsum; 1RY7; -.
DR   PDBsum; 2LZL; -.
DR   PDBsum; 4K33; -.
DR   PDBsum; 6LVM; -.
DR   PDBsum; 6PNX; -.
DR   PDBsum; 7DHL; -.
DR   AlphaFoldDB; P22607; -.
DR   BMRB; P22607; -.
DR   SASBDB; P22607; -.
DR   SMR; P22607; -.
DR   BioGRID; 108552; 159.
DR   DIP; DIP-4016N; -.
DR   IntAct; P22607; 537.
DR   MINT; P22607; -.
DR   STRING; 9606.ENSP00000339824; -.
DR   BindingDB; P22607; -.
DR   ChEMBL; CHEMBL2742; -.
DR   DrugBank; DB12147; Erdafitinib.
DR   DrugBank; DB12010; Fostamatinib.
DR   DrugBank; DB11886; Infigratinib.
DR   DrugBank; DB09078; Lenvatinib.
DR   DrugBank; DB09079; Nintedanib.
DR   DrugBank; DB06589; Pazopanib.
DR   DrugBank; DB15102; Pemigatinib.
DR   DrugBank; DB08901; Ponatinib.
DR   DrugBank; DB15685; Selpercatinib.
DR   DrugBank; DB05014; XL999.
DR   DrugCentral; P22607; -.
DR   GuidetoPHARMACOLOGY; 1810; -.
DR   GlyGen; P22607; 7 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P22607; -.
DR   PhosphoSitePlus; P22607; -.
DR   BioMuta; FGFR3; -.
DR   DMDM; 120050; -.
DR   EPD; P22607; -.
DR   jPOST; P22607; -.
DR   MassIVE; P22607; -.
DR   PaxDb; P22607; -.
DR   PeptideAtlas; P22607; -.
DR   PRIDE; P22607; -.
DR   ProteomicsDB; 54005; -. [P22607-1]
DR   ProteomicsDB; 54006; -. [P22607-2]
DR   ProteomicsDB; 54007; -. [P22607-3]
DR   ProteomicsDB; 54008; -. [P22607-4]
DR   ABCD; P22607; 3 sequenced antibodies.
DR   Antibodypedia; 3787; 763 antibodies from 44 providers.
DR   DNASU; 2261; -.
DR   Ensembl; ENST00000340107.8; ENSP00000339824.4; ENSG00000068078.20. [P22607-2]
DR   Ensembl; ENST00000352904.6; ENSP00000231803.1; ENSG00000068078.20. [P22607-3]
DR   Ensembl; ENST00000440486.8; ENSP00000414914.2; ENSG00000068078.20. [P22607-1]
DR   GeneID; 2261; -.
DR   KEGG; hsa:2261; -.
DR   MANE-Select; ENST00000440486.8; ENSP00000414914.2; NM_000142.5; NP_000133.1.
DR   UCSC; uc003gdr.3; human. [P22607-1]
DR   CTD; 2261; -.
DR   DisGeNET; 2261; -.
DR   GeneCards; FGFR3; -.
DR   GeneReviews; FGFR3; -.
DR   HGNC; HGNC:3690; FGFR3.
DR   HPA; ENSG00000068078; Tissue enhanced (brain, esophagus, skin).
DR   MalaCards; FGFR3; -.
DR   MIM; 100800; phenotype.
DR   MIM; 109800; phenotype.
DR   MIM; 134934; gene.
DR   MIM; 146000; phenotype.
DR   MIM; 149730; phenotype.
DR   MIM; 162900; phenotype.
DR   MIM; 182000; phenotype.
DR   MIM; 187600; phenotype.
DR   MIM; 187601; phenotype.
DR   MIM; 254500; phenotype.
DR   MIM; 273300; phenotype.
DR   MIM; 602849; phenotype.
DR   MIM; 603956; phenotype.
DR   MIM; 610474; phenotype.
DR   MIM; 612247; phenotype.
DR   MIM; 616482; phenotype.
DR   neXtProt; NX_P22607; -.
DR   OpenTargets; ENSG00000068078; -.
DR   Orphanet; 15; Achondroplasia.
DR   Orphanet; 85164; Camptodactyly-tall stature-scoliosis-hearing loss syndrome.
DR   Orphanet; 93262; Crouzon syndrome-acanthosis nigricans syndrome.
DR   Orphanet; 251579; Giant cell glioblastoma.
DR   Orphanet; 251576; Gliosarcoma.
DR   Orphanet; 429; Hypochondroplasia.
DR   Orphanet; 2363; Lacrimoauriculodentodigital syndrome.
DR   Orphanet; 53271; Muenke syndrome.
DR   Orphanet; 35099; Non-syndromic bicoronal craniosynostosis.
DR   Orphanet; 794; Saethre-Chotzen syndrome.
DR   Orphanet; 85165; Severe achondroplasia-developmental delay-acanthosis nigricans syndrome.
DR   Orphanet; 1860; Thanatophoric dysplasia type 1.
DR   Orphanet; 93274; Thanatophoric dysplasia type 2.
DR   PharmGKB; PA28129; -.
DR   VEuPathDB; HostDB:ENSG00000068078; -.
DR   eggNOG; KOG0200; Eukaryota.
DR   GeneTree; ENSGT00940000159880; -.
DR   HOGENOM; CLU_000288_74_3_1; -.
DR   InParanoid; P22607; -.
DR   OMA; PTIYWLK; -.
DR   OrthoDB; 220433at2759; -.
DR   PhylomeDB; P22607; -.
DR   TreeFam; TF316307; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P22607; -.
DR   Reactome; R-HSA-109704; PI3K Cascade.
DR   Reactome; R-HSA-1257604; PIP3 activates AKT signaling.
DR   Reactome; R-HSA-1839130; Signaling by activated point mutants of FGFR3.
DR   Reactome; R-HSA-190371; FGFR3b ligand binding and activation. [P22607-2]
DR   Reactome; R-HSA-190372; FGFR3c ligand binding and activation. [P22607-1]
DR   Reactome; R-HSA-2033515; t(4;14) translocations of FGFR3.
DR   Reactome; R-HSA-2219530; Constitutive Signaling by Aberrant PI3K in Cancer.
DR   Reactome; R-HSA-5654227; Phospholipase C-mediated cascade, FGFR3.
DR   Reactome; R-HSA-5654704; SHC-mediated cascade:FGFR3.
DR   Reactome; R-HSA-5654706; FRS-mediated FGFR3 signaling.
DR   Reactome; R-HSA-5654710; PI-3K cascade:FGFR3.
DR   Reactome; R-HSA-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-HSA-5655332; Signaling by FGFR3 in disease.
DR   Reactome; R-HSA-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-HSA-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-HSA-8853334; Signaling by FGFR3 fusions in cancer.
DR   SignaLink; P22607; -.
DR   SIGNOR; P22607; -.
DR   BioGRID-ORCS; 2261; 15 hits in 1115 CRISPR screens.
DR   ChiTaRS; FGFR3; human.
DR   EvolutionaryTrace; P22607; -.
DR   GeneWiki; Fibroblast_growth_factor_receptor_3; -.
DR   GenomeRNAi; 2261; -.
DR   Pharos; P22607; Tclin.
DR   PRO; PR:P22607; -.
DR   Proteomes; UP000005640; Chromosome 4.
DR   RNAct; P22607; protein.
DR   Bgee; ENSG00000068078; Expressed in upper leg skin and 179 other tissues.
DR   ExpressionAtlas; P22607; baseline and differential.
DR   Genevisible; P22607; HS.
DR   GO; GO:0009986; C:cell surface; IEA:Ensembl.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:HPA.
DR   GO; GO:0005576; C:extracellular region; IEA:UniProtKB-SubCell.
DR   GO; GO:0005794; C:Golgi apparatus; IDA:UniProtKB.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0030133; C:transport vesicle; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IDA:UniProtKB.
DR   GO; GO:0005007; F:fibroblast growth factor receptor activity; IMP:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0070977; P:bone maturation; ISS:BHF-UCL.
DR   GO; GO:0030282; P:bone mineralization; ISS:BHF-UCL.
DR   GO; GO:0060349; P:bone morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0007267; P:cell-cell signaling; IEA:Ensembl.
DR   GO; GO:0002062; P:chondrocyte differentiation; TAS:UniProtKB.
DR   GO; GO:0035988; P:chondrocyte proliferation; TAS:UniProtKB.
DR   GO; GO:0003416; P:endochondral bone growth; TAS:UniProtKB.
DR   GO; GO:0001958; P:endochondral ossification; TAS:UniProtKB.
DR   GO; GO:1902178; P:fibroblast growth factor receptor apoptotic signaling pathway; IMP:UniProtKB.
DR   GO; GO:0008543; P:fibroblast growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0000165; P:MAPK cascade; TAS:ProtInc.
DR   GO; GO:0048640; P:negative regulation of developmental growth; ISS:BHF-UCL.
DR   GO; GO:0018108; P:peptidyl-tyrosine phosphorylation; IDA:UniProtKB.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:UniProtKB.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IMP:UniProtKB.
DR   GO; GO:0043552; P:positive regulation of phosphatidylinositol 3-kinase activity; IMP:UniProtKB.
DR   GO; GO:0010518; P:positive regulation of phospholipase activity; IMP:UniProtKB.
DR   GO; GO:0042531; P:positive regulation of tyrosine phosphorylation of STAT protein; IMP:UniProtKB.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0001501; P:skeletal system development; TAS:ProtInc.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   Gene3D; 2.60.40.10; -; 3.
DR   InterPro; IPR016248; FGF_rcpt_fam.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR036179; Ig-like_dom_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   PIRSF; PIRSF000628; FGFR; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00409; IG; 3.
DR   SMART; SM00408; IGc2; 3.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF48726; SSF48726; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50835; IG_LIKE; 3.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; ATP-binding; Cell membrane;
KW   Chromosomal rearrangement; Craniosynostosis; Cytoplasmic vesicle; Deafness;
KW   Disease variant; Disulfide bond; Dwarfism; Ectodermal dysplasia;
KW   Endoplasmic reticulum; Glycoprotein; Immunoglobulin domain; Kinase;
KW   Lacrimo-auriculo-dento-digital syndrome; Membrane; Nucleotide-binding;
KW   Phosphoprotein; Receptor; Reference proteome; Repeat; Secreted; Signal;
KW   Transferase; Transmembrane; Transmembrane helix; Tyrosine-protein kinase;
KW   Ubl conjugation.
FT   SIGNAL          1..22
FT   CHAIN           23..806
FT                   /note="Fibroblast growth factor receptor 3"
FT                   /id="PRO_0000016785"
FT   TOPO_DOM        23..375
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        376..396
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        397..806
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          24..126
FT                   /note="Ig-like C2-type 1"
FT   DOMAIN          151..244
FT                   /note="Ig-like C2-type 2"
FT   DOMAIN          253..355
FT                   /note="Ig-like C2-type 3"
FT   DOMAIN          472..761
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          126..153
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          765..806
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        770..787
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        617
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         478..486
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         508
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         444
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61851"
FT   MOD_RES         445
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61851"
FT   MOD_RES         647
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:8754806"
FT   MOD_RES         648
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000305|PubMed:8754806"
FT   MOD_RES         724
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11294897"
FT   MOD_RES         760
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:19286672"
FT   CARBOHYD        98
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        225
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        262
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        294
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        315
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        328
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        61..109
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        176..228
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   DISULFID        275..339
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00114"
FT   VAR_SEQ         311..422
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:11703096"
FT                   /id="VSP_002989"
FT   VAR_SEQ         311..358
FT                   /note="TAGANTTDKELEVLSLHNVTFEDAGEYTCLAGNSIGFSHHSAWLVVLP ->
FT                   SWISESVEADVRLRLANVSERDGGEYLCRATNFIGVAEKAFWLSVHGPRA (in
FT                   isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7495869"
FT                   /id="VSP_002988"
FT   VAR_SEQ         654..806
FT                   /note="GRLPVKWMAPEALFDRVYTHQSDVWSFGVLLWEIFTLGGSPYPGIPVEELFK
FT                   LLKEGHRMDKPANCTHDLYMIMRECWHAAPSQRPTFKQLVEDLDRVLTVTSTDEYLDLS
FT                   APFEQYSPGGQDTPSSSSSGDDSVFAHDLLPPAPPSSGGSRT -> LVLWGPALGDLHA
FT                   GGLPVPRHPCGGALQAAEGGPPHGQARQLHTRPVHDHAGVLACRALPEAHLQAAGGGPG
FT                   PCPYRDVHRRVPGPVGAFRAVLPGWPGHPQLQLLRGRLRVCPRPAAPGPTQQWGLADVK
FT                   GHWSPTM (in isoform 4)"
FT                   /evidence="ECO:0000303|Ref.3"
FT                   /id="VSP_040945"
FT   VARIANT         65
FT                   /note="G -> R (in dbSNP:rs2305178)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022167"
FT   VARIANT         79
FT                   /note="T -> S (in a lung adenocarcinoma sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042207"
FT   VARIANT         228
FT                   /note="C -> R (in a colorectal adenocarcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042208"
FT   VARIANT         248
FT                   /note="R -> C (in KERSEB, BLC, keratinocytic
FT                   non-epidermolytic nevus and TD1; severe and lethal; also
FT                   found as somatic mutation in one patient with multiple
FT                   myeloma; constitutive dimerization and kinase activation;
FT                   dbSNP:rs121913482)"
FT                   /evidence="ECO:0000269|PubMed:10360402,
FT                   ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:11529856,
FT                   ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094,
FT                   ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:7773297,
FT                   ECO:0000269|PubMed:8845844"
FT                   /id="VAR_004148"
FT   VARIANT         249
FT                   /note="S -> C (in KERSEB, BLC, cervical cancer and TD1;
FT                   dbSNP:rs121913483)"
FT                   /evidence="ECO:0000269|PubMed:10360402,
FT                   ECO:0000269|PubMed:10471491, ECO:0000269|PubMed:15772091,
FT                   ECO:0000269|PubMed:8589699, ECO:0000269|PubMed:8845844"
FT                   /id="VAR_004149"
FT   VARIANT         250
FT                   /note="P -> R (in MNKS; also some individuals with
FT                   autosomal dominant congenital sensorineural deafness
FT                   without craniosynostosis; dbSNP:rs4647924)"
FT                   /evidence="ECO:0000269|PubMed:11746040,
FT                   ECO:0000269|PubMed:9042914, ECO:0000269|PubMed:9525367,
FT                   ECO:0000269|PubMed:9950359"
FT                   /id="VAR_004150"
FT   VARIANT         322
FT                   /note="E -> K (in colorectal cancer; dbSNP:rs121913111)"
FT                   /evidence="ECO:0000269|PubMed:11325814"
FT                   /id="VAR_018388"
FT   VARIANT         338
FT                   /note="T -> M"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042209"
FT   VARIANT         370
FT                   /note="G -> C (in KERSEB, BLC, keratinocytic
FT                   non-epidermolytic nevus and TD1; dbSNP:rs121913479)"
FT                   /evidence="ECO:0000269|PubMed:10471491,
FT                   ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:16841094,
FT                   ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9790257"
FT                   /id="VAR_004151"
FT   VARIANT         371
FT                   /note="S -> C (in KERSEB and TD1; dbSNP:rs121913484)"
FT                   /evidence="ECO:0000269|PubMed:15772091,
FT                   ECO:0000269|PubMed:7773297"
FT                   /id="VAR_004152"
FT   VARIANT         373
FT                   /note="Y -> C (in KERSEB and TD1; disulfide-linked dimer
FT                   with constitutive kinase activation; dbSNP:rs121913485)"
FT                   /evidence="ECO:0000269|PubMed:10360402,
FT                   ECO:0000269|PubMed:15772091, ECO:0000269|PubMed:17509076,
FT                   ECO:0000269|PubMed:8845844, ECO:0000269|PubMed:9207791"
FT                   /id="VAR_004153"
FT   VARIANT         375
FT                   /note="G -> C (in ACH; dbSNP:rs75790268)"
FT                   /evidence="ECO:0000269|PubMed:7758520"
FT                   /id="VAR_004154"
FT   VARIANT         380
FT                   /note="G -> R (in keratinocytic non-epidermolytic nevus and
FT                   ACH; very common mutation; constitutively activated kinase
FT                   with impaired internalization and degradation, resulting in
FT                   prolonged FGFR3 signaling; dbSNP:rs28931614)"
FT                   /evidence="ECO:0000269|PubMed:10611230,
FT                   ECO:0000269|PubMed:12297284, ECO:0000269|PubMed:16841094,
FT                   ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:7847369,
FT                   ECO:0000269|PubMed:8078586, ECO:0000269|PubMed:8599935"
FT                   /id="VAR_004155"
FT   VARIANT         384
FT                   /note="F -> L (in dbSNP:rs17881656)"
FT                   /evidence="ECO:0000269|PubMed:17344846, ECO:0000269|Ref.4"
FT                   /id="VAR_022168"
FT   VARIANT         391
FT                   /note="A -> E (in CAN; dbSNP:rs28931615)"
FT                   /evidence="ECO:0000269|PubMed:17935505,
FT                   ECO:0000269|PubMed:7493034"
FT                   /id="VAR_004156"
FT   VARIANT         441
FT                   /note="A -> T (in dbSNP:rs17884368)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022169"
FT   VARIANT         513
FT                   /note="D -> N (in LADDS; dbSNP:rs121913112)"
FT                   /evidence="ECO:0000269|PubMed:16501574"
FT                   /id="VAR_029887"
FT   VARIANT         538
FT                   /note="I -> V (in hypochondroplasia; dbSNP:rs80053154)"
FT                   /evidence="ECO:0000269|PubMed:10215410"
FT                   /id="VAR_004157"
FT   VARIANT         540
FT                   /note="N -> K (in hypochondroplasia; dbSNP:rs28933068)"
FT                   /evidence="ECO:0000269|PubMed:7670477"
FT                   /id="VAR_004158"
FT   VARIANT         540
FT                   /note="N -> S (in hypochondroplasia; mild;
FT                   dbSNP:rs77722678)"
FT                   /evidence="ECO:0000269|PubMed:10777366,
FT                   ECO:0000269|PubMed:12707965"
FT                   /id="VAR_018389"
FT   VARIANT         540
FT                   /note="N -> T (in hypochondroplasia; dbSNP:rs77722678)"
FT                   /evidence="ECO:0000269|PubMed:9452043"
FT                   /id="VAR_004159"
FT   VARIANT         621
FT                   /note="R -> H (in CATSHLS; dbSNP:rs121913113)"
FT                   /evidence="ECO:0000269|PubMed:17033969"
FT                   /id="VAR_029108"
FT   VARIANT         646
FT                   /note="D -> N"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042210"
FT   VARIANT         650
FT                   /note="K -> E (in KERSEB, TD2, TGCT and BLC; bladder
FT                   transitional cell carcinoma; somatic mutation;
FT                   constitutively activated kinase with impaired
FT                   internalization and degradation, resulting in prolonged
FT                   FGFR3 signaling; dbSNP:rs78311289)"
FT                   /evidence="ECO:0000269|PubMed:10471491,
FT                   ECO:0000269|PubMed:11294897, ECO:0000269|PubMed:12297284,
FT                   ECO:0000269|PubMed:14534538, ECO:0000269|PubMed:15772091,
FT                   ECO:0000269|PubMed:17145761, ECO:0000269|PubMed:17344846,
FT                   ECO:0000269|PubMed:17561467, ECO:0000269|PubMed:19855393,
FT                   ECO:0000269|PubMed:7773297, ECO:0000269|PubMed:8754806,
FT                   ECO:0000269|PubMed:9207791"
FT                   /id="VAR_004160"
FT   VARIANT         650
FT                   /note="K -> M (in KERSEB, ACH, TD1 and SADDAN;
FT                   constitutively activated kinase with impaired
FT                   internalization and degradation, resulting in prolonged
FT                   FGFR3 signaling; dbSNP:rs121913105)"
FT                   /evidence="ECO:0000269|PubMed:10053006,
FT                   ECO:0000269|PubMed:10671061, ECO:0000269|PubMed:15772091,
FT                   ECO:0000269|PubMed:17509076, ECO:0000269|PubMed:17561467,
FT                   ECO:0000269|PubMed:9207791"
FT                   /id="VAR_004161"
FT   VARIANT         650
FT                   /note="K -> Q (in hypochondroplasia and BLC; in
FT                   hypochondroplasia the form is milder than that seen in
FT                   individuals with the K-540 or M-650 mutations;
FT                   constitutively activated kinase; dbSNP:rs78311289)"
FT                   /evidence="ECO:0000269|PubMed:11055896,
FT                   ECO:0000269|PubMed:11314002, ECO:0000269|PubMed:8754806"
FT                   /id="VAR_018390"
FT   VARIANT         717
FT                   /note="A -> T (in dbSNP:rs17882190)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022170"
FT   VARIANT         726
FT                   /note="I -> F (in dbSNP:rs17880763)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_022171"
FT   MUTAGEN         508
FT                   /note="K->A: Loss of kinase activity. Abolishes
FT                   ubiquitination."
FT                   /evidence="ECO:0000269|PubMed:12297284,
FT                   ECO:0000269|PubMed:16410555"
FT   MUTAGEN         577
FT                   /note="Y->F: Minor effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11294897"
FT   MUTAGEN         650
FT                   /note="K->D: Constitutively activated kinase."
FT   MUTAGEN         650
FT                   /note="K->L: Constitutively activated kinase."
FT   MUTAGEN         724
FT                   /note="Y->F: Strongly reduced kinase activity. Strongly
FT                   reduced mitogen activity."
FT                   /evidence="ECO:0000269|PubMed:11294897"
FT   MUTAGEN         760
FT                   /note="Y->F: Minor effect on kinase activity."
FT                   /evidence="ECO:0000269|PubMed:11294897"
FT   MUTAGEN         770
FT                   /note="Y->F: Minor effect on kinase activity. Increased
FT                   mitogen activity."
FT                   /evidence="ECO:0000269|PubMed:11294897"
FT   CONFLICT        395
FT                   /note="L -> V (in Ref. 7; AAA58470)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        421
FT                   /note="R -> RQ (in Ref. 3; BAD92678)"
FT                   /evidence="ECO:0000305"
FT   STRAND          163..167
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          172..175
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          185..187
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   TURN            208..211
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          212..215
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   HELIX           220..222
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          226..232
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          235..246
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          263..268
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          271..273
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          283..289
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   HELIX           293..295
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          302..304
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          324..326
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          335..345
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          348..357
FT                   /evidence="ECO:0007829|PDB:1RY7"
FT   STRAND          369..372
FT                   /evidence="ECO:0007829|PDB:2LZL"
FT   HELIX           374..398
FT                   /evidence="ECO:0007829|PDB:2LZL"
FT   TURN            463..465
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           469..471
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          472..480
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          485..493
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          502..509
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           516..532
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          541..545
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          547..550
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          552..556
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           563..568
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           591..610
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           620..622
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          623..625
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   STRAND          631..633
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   TURN            643..645
FT                   /evidence="ECO:0007829|PDB:6LVM"
FT   STRAND          646..649
FT                   /evidence="ECO:0007829|PDB:4K33"
FT   HELIX           658..660
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           663..668
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           673..688
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           700..702
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           703..708
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           721..730
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           735..737
FT                   /evidence="ECO:0007829|PDB:6PNX"
FT   HELIX           741..754
FT                   /evidence="ECO:0007829|PDB:6PNX"
SQ   SEQUENCE   806 AA;  87710 MW;  BC5EA75EA46F447E CRC64;
     MGAPACALAL CVAVAIVAGA SSESLGTEQR VVGRAAEVPG PEPGQQEQLV FGSGDAVELS
     CPPPGGGPMG PTVWVKDGTG LVPSERVLVG PQRLQVLNAS HEDSGAYSCR QRLTQRVLCH
     FSVRVTDAPS SGDDEDGEDE AEDTGVDTGA PYWTRPERMD KKLLAVPAAN TVRFRCPAAG
     NPTPSISWLK NGREFRGEHR IGGIKLRHQQ WSLVMESVVP SDRGNYTCVV ENKFGSIRQT
     YTLDVLERSP HRPILQAGLP ANQTAVLGSD VEFHCKVYSD AQPHIQWLKH VEVNGSKVGP
     DGTPYVTVLK TAGANTTDKE LEVLSLHNVT FEDAGEYTCL AGNSIGFSHH SAWLVVLPAE
     EELVEADEAG SVYAGILSYG VGFFLFILVV AAVTLCRLRS PPKKGLGSPT VHKISRFPLK
     RQVSLESNAS MSSNTPLVRI ARLSSGEGPT LANVSELELP ADPKWELSRA RLTLGKPLGE
     GCFGQVVMAE AIGIDKDRAA KPVTVAVKML KDDATDKDLS DLVSEMEMMK MIGKHKNIIN
     LLGACTQGGP LYVLVEYAAK GNLREFLRAR RPPGLDYSFD TCKPPEEQLT FKDLVSCAYQ
     VARGMEYLAS QKCIHRDLAA RNVLVTEDNV MKIADFGLAR DVHNLDYYKK TTNGRLPVKW
     MAPEALFDRV YTHQSDVWSF GVLLWEIFTL GGSPYPGIPV EELFKLLKEG HRMDKPANCT
     HDLYMIMREC WHAAPSQRPT FKQLVEDLDR VLTVTSTDEY LDLSAPFEQY SPGGQDTPSS
     SSSGDDSVFA HDLLPPAPPS SGGSRT
//
